| Year |
Citation |
Score |
| 2024 |
Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson RC, Almazan AJ, Scarfò I, Bouffard AA, Bailey SR, Anekal PV, Montero Lopis P, Nieman LT, Song Y, Xu KH, ... ... Jaffee EM, et al. Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38393682 DOI: 10.1158/1078-0432.CCR-23-3841 |
0.416 |
|
| 2024 |
Zabransky DJ, Chhabra Y, Fane ME, Kartalia E, Leatherman JM, Hüser L, Zimmerman JW, Delitto D, Han S, Armstrong TD, Guinn S, Pramod S, Thompson ED, Hughes SJ, O'Connell J, ... ... Jaffee EM, et al. Fibroblasts in the aged pancreas drive pancreatic cancer progression. Cancer Research. PMID 38330147 DOI: 10.1158/0008-5472.CAN-24-0086 |
0.301 |
|
| 2024 |
Wang J, Gai J, Zhang T, Niu N, Qi H, Thomas DL, Li K, Xia T, Rodriguez C, Parkinson R, Durham J, McPhaul T, Narang AK, Anders RA, Osipov A, ... ... Jaffee EM, et al. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Science Advances. 10: eadk1827. PMID 38324679 DOI: 10.1126/sciadv.adk1827 |
0.38 |
|
| 2023 |
Sidiropoulos DN, Ho WJ, Jaffee EM, Kagohara LT, Fertig EJ. Systems immunology spanning tumors, lymph nodes, and periphery. Cell Reports Methods. 100670. PMID 38086385 DOI: 10.1016/j.crmeth.2023.100670 |
0.306 |
|
| 2023 |
Huff AL, Longway G, Mitchell JT, Andaloori L, Davis-Marcisak E, Chen F, Lyman MR, Wang R, Mathew J, Barrett B, Rahman S, Leatherman J, Yarchoan M, Azad NS, Yegnasubramanian S, ... ... Jaffee EM, et al. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy. Jci Insight. 8. PMID 38063199 DOI: 10.1172/jci.insight.174027 |
0.483 |
|
| 2023 |
Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin SM, Danilova L, Lee JW, Sidiropoulos DN, Mitchell S, Munjal K, Howe K, Bendinelli KJ, Qi H, Mo G, Montagne J, ... ... Jaffee EM, et al. Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockade. Biorxiv : the Preprint Server For Biology. PMID 37904980 DOI: 10.1101/2023.10.16.562104 |
0.39 |
|
| 2023 |
Xu GJ, Loberg MA, Gallant JN, Sheng Q, Chen SC, Lehmann BD, Shaddy SM, Tigue ML, Phifer CJ, Wang L, Saab-Chalhoub MW, Dehan LM, Wei Q, Chen R, Li B, ... ... Jaffee EM, et al. Molecular signature incorporating the immune microenvironment enhances thyroid cancer outcome prediction. Cell Genomics. 3: 100409. PMID 37868034 DOI: 10.1016/j.xgen.2023.100409 |
0.684 |
|
| 2023 |
Jayaraman S, Montagne JM, Nirschl TR, Marcisak E, Johnson J, Huff A, Hsiao MH, Nauroth J, Heumann T, Zarif JC, Jaffee EM, Azad N, Fertig EJ, Zaidi N, Larman HB. Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses. Cell Reports Methods. 100600. PMID 37776855 DOI: 10.1016/j.crmeth.2023.100600 |
0.334 |
|
| 2023 |
Heumann T, Judkins C, Li K, Lim SJ, Hoare J, Parkinson R, Cao H, Zhang T, Gai J, Celiker B, Zhu Q, McPhaul T, Durham J, Purtell K, Klein R, ... ... Jaffee E, et al. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nature Communications. 14: 3650. PMID 37339979 DOI: 10.1038/s41467-023-39196-9 |
0.355 |
|
| 2023 |
Montagne JM, Jaffee EM, Fertig EJ. Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy. Journal of Immunology (Baltimore, Md. : 1950). 210: 859-868. PMID 36947820 DOI: 10.4049/jimmunol.2200660 |
0.377 |
|
| 2023 |
Chia L, Wang B, Kim JH, Luo LZ, Shuai S, Herrera I, Chen SY, Li L, Xian L, Huso T, Heydarian M, Reddy K, Sung WJ, Ishiyama S, Guo G, ... Jaffee E, et al. HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation. The Journal of Clinical Investigation. 133. PMID 36919699 DOI: 10.1172/JCI151601 |
0.317 |
|
| 2023 |
Zhang S, Yuan L, Danilova L, Mo G, Zhu Q, Deshpande A, Bell ATF, Elisseeff J, Popel AS, Anders RA, Jaffee EM, Yarchoan M, Fertig EJ, Kagohara LT. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Biorxiv : the Preprint Server For Biology. PMID 36712023 DOI: 10.1101/2023.01.10.523481 |
0.373 |
|
| 2022 |
Li K, Tandurella JA, Gai J, Zhu Q, Lim SJ, Thomas DL, Xia T, Mo G, Mitchell JT, Montagne J, Lyman M, Danilova LV, Zimmerman JW, Kinny-Köster B, Zhang T, ... ... Jaffee EM, et al. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Cancer Cell. PMID 36306792 DOI: 10.1016/j.ccell.2022.10.001 |
0.444 |
|
| 2022 |
Sidiropoulos DN, Stein-O'Brien GL, Danilova L, Gross NE, Charmsaz S, Xavier S, Leatherman J, Wang H, Yarchoan M, Jaffee EM, Fertig EJ, Ho WJ. Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials. Jci Insight. 7. PMID 36214223 DOI: 10.1172/jci.insight.160398 |
0.321 |
|
| 2022 |
Mi H, Sivagnanam S, Betts CB, Liudahl SM, Jaffee EM, Coussens LM, Popel AS. Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers. Cancer Research. PMID 36112643 DOI: 10.1158/0008-5472.CAN-22-1190 |
0.385 |
|
| 2022 |
Sidiropoulos DN, Rafie CI, Jang JK, Castanon S, Baugh AG, Gonzalez E, Christmas BJ, Narumi VH, Davis-Marcisak EF, Sharma G, Bigelow E, Vaghasia A, Gupta A, Skaist A, Considine M, ... ... Jaffee EM, et al. Entinostat decreases immune suppression to promote anti-tumor responses in a HER2+ breast tumor microenvironment. Cancer Immunology Research. PMID 35201318 DOI: 10.1158/2326-6066.CIR-21-0170 |
0.374 |
|
| 2022 |
Angstadt S, Zhu Q, Jaffee EM, Robinson DN, Anders RA. Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications. Frontiers in Oncology. 12: 809179. PMID 35174086 DOI: 10.3389/fonc.2022.809179 |
0.339 |
|
| 2021 |
Delitto D, Zabransky DJ, Chen F, Thompson ED, Zimmerman JW, Armstrong TD, Leatherman JM, Suri R, Lopez-Vidal TY, Huff AL, Lyman MR, Guinn SR, Baretti M, Kagohara LT, Ho WJ, ... ... Jaffee EM, et al. Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Oncoimmunology. 10: 2001159. PMID 34777919 DOI: 10.1080/2162402X.2021.2001159 |
0.431 |
|
| 2021 |
Markov SD, Caffrey TC, O' Connell KA, Grunkemeyer JA, Shin S, Hanson R, Patil PP, Shukla SK, Gonzalez D, Crawford AJ, Vance KE, Huang Y, Eberle KC, Radhakrishnan P, Grandgenett PM, ... ... Jaffee EM, et al. IgE-based therapeutic combination enhances anti-tumor response in preclinical models of pancreatic cancer. Molecular Cancer Therapeutics. PMID 34625505 DOI: 10.1158/1535-7163.MCT-21-0368 |
0.419 |
|
| 2021 |
Dennison L, Ruggieri A, Mohan A, Leatherman J, Cruz K, Woolman S, Azad N, Lesinski GB, Jaffee EM, Yarchoan M. Context-Dependent Immunomodulatory Effects of MEK Inhibition are Enhanced with T-cell Agonist Therapy. Cancer Immunology Research. PMID 34389557 DOI: 10.1158/2326-6066.CIR-21-0147 |
0.447 |
|
| 2021 |
Davis-Marcisak EF, Fitzgerald AA, Kessler MD, Danilova L, Jaffee EM, Zaidi N, Weiner LM, Fertig EJ. Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors. Genome Medicine. 13: 129. PMID 34376232 DOI: 10.1186/s13073-021-00944-5 |
0.424 |
|
| 2021 |
Ho WJ, Croessmann S, Lin J, Phyo ZH, Charmsaz S, Danilova L, Mohan AA, Gross NE, Chen F, Dong J, Aggarwal D, Bai Y, Wang J, He J, Leatherman JM, ... ... Jaffee EM, et al. Systemic inhibition of PTPN22 augments anticancer immunity. The Journal of Clinical Investigation. PMID 34283806 DOI: 10.1172/JCI146950 |
0.388 |
|
| 2021 |
Roussos Torres ET, Rafie CI, Wang C, Lim D, Brufsky AM, LoRusso PM, Eder JP, Chung V, Downs M, Geare M, Piekarz RL, Streicher H, Anforth L, Rudek MA, Zhu Q, ... ... Jaffee EM, et al. Phase 1 Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34135021 DOI: 10.1158/1078-0432.CCR-20-5017 |
0.324 |
|
| 2021 |
Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb CW, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, ... ... Jaffee EM, et al. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34112709 DOI: 10.1158/1078-0432.CCR-21-1047 |
0.328 |
|
| 2021 |
Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, Hwang S, Grossblatt-Wait A, Leis KR, Larson W, Lavoie MB, Robinson P, Dias Costa A, Vayrynen SA, Clancy TE, ... ... Jaffee EM, et al. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discovery. PMID 33727309 DOI: 10.1158/2159-8290.CD-20-0841 |
0.348 |
|
| 2021 |
Charmsaz S, Gross N, Jaffee E, Ho WJ. A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors. Jci Insight. PMID 33690223 DOI: 10.1172/jci.insight.143283 |
0.377 |
|
| 2021 |
Bever KM, Thomas DL, Zhang J, Diaz Rivera EA, Rosner GL, Zhu Q, Nauroth JM, Christmas B, Thompson ED, Anders RA, Judkins C, Liu M, Jaffee EM, Ahuja N, Zheng L, et al. A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint. Clinical Epigenetics. 13: 25. PMID 33531075 DOI: 10.1186/s13148-021-01014-8 |
0.373 |
|
| 2021 |
Lam H, McNeil LK, Starobinets H, DeVault VL, Cohen RB, Twardowski P, Johnson ML, Gillison ML, Stein MN, Vaishampayan UN, DeCillis AP, Foti JJ, Vemulapalli V, Tjon E, Ferber K, ... ... Jaffee EM, et al. An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. Cancer Discovery. PMID 33504579 DOI: 10.1158/2159-8290.CD-20-0377 |
0.49 |
|
| 2020 |
Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell KM, Carethers JM, Jaffee EM, Wherry EJ, Soria JC, D'Souza G. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discovery. PMID 33355178 DOI: 10.1158/2159-8290.CD-20-1817 |
0.307 |
|
| 2020 |
Zheng L, Ding D, Edil BH, Judkin C, Durham JN, Thomas DL, Bever KM, Mo G, Solt S, Hoare J, Bhattacharya R, Zhu Q, Osipov A, Onners BL, Purtell K, ... ... Jaffee EM, et al. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33277370 DOI: 10.1158/1078-0432.CCR-20-2974 |
0.39 |
|
| 2020 |
Mi H, Gong C, Sulam J, Fertig EJ, Szalay AS, Jaffee EM, Stearns V, Emens LA, Cimino-Mathews AM, Popel AS. Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer. Frontiers in Physiology. 11: 583333. PMID 33192595 DOI: 10.3389/fphys.2020.583333 |
0.309 |
|
| 2020 |
Mirando AC, Patil A, Rafie CI, Christmas BJ, Pandey NB, Stearns V, Jaffee EM, Roussos Torres ET, Popel AS. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide. Oncoimmunology. 9: 1760685. PMID 32923118 DOI: 10.1080/2162402X.2020.1760685 |
0.515 |
|
| 2020 |
Zaidi N, Soban M, Chen F, Kinkead H, Mathew J, Yarchoan M, Armstrong TD, Haider S, Jaffee EM. Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development. Jci Insight. 5. PMID 32879142 DOI: 10.1172/Jci.Insight.136991 |
0.463 |
|
| 2020 |
Seppälä TT, Zimmerman JW, Sereni E, Plenker D, Suri R, Rozich N, Blair A, Thomas DL, Teinor J, Javed A, Patel H, Cameron JL, Burns WR, He J, Tuveson DA, ... Jaffee EM, et al. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Annals of Surgery. PMID 32657929 DOI: 10.1097/Sla.0000000000004200 |
0.329 |
|
| 2020 |
Chan IS, Knútsdóttir H, Ramakrishnan G, Padmanaban V, Warrier M, Ramirez JC, Dunworth M, Zhang H, Jaffee EM, Bader JS, Ewald AJ. Cancer cells educate natural killer cells to a metastasis-promoting cell state. The Journal of Cell Biology. 219. PMID 32645139 DOI: 10.1083/Jcb.202001134 |
0.442 |
|
| 2020 |
Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners BL, Ferguson A, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, ... ... Jaffee EM, et al. A Phase 2 Study of Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32591464 DOI: 10.1158/1078-0432.Ccr-20-1025 |
0.48 |
|
| 2020 |
Osipov A, Lim SJ, Popovic A, Azad NS, Laheru DA, Zheng L, Jaffee EM, Wang H, Yarchoan M. Tumor Mutational Burden, Toxicity and Response of Immune Checkpoint Inhibitors (ICIs) Targeting PD(L)1, CTLA-4, and Combination: A Meta-Regression Analysis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32586938 DOI: 10.1158/1078-0432.Ccr-20-0458 |
0.411 |
|
| 2020 |
Bever KM, Borazanci EH, Thompson EA, Durham JN, Pinero K, Jameson GS, Vrana A, Liu M, Wilt C, Wu AA, Fu W, Wang H, Yin Y, Leal JP, Jesus-Acosta A, ... ... Jaffee EM, et al. An exploratory study of metformin with or without rapamycin as maintenance therapy after induction chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncotarget. 11: 1929-1941. PMID 32523648 DOI: 10.18632/Oncotarget.27586 |
0.4 |
|
| 2020 |
Yarchoan M, Ho WJ, Mohan A, Shah Y, Vithayathil T, Leatherman J, Dennison L, Zaidi N, Ganguly S, Woolman S, Cruz K, Armstrong TD, Jaffee EM. Effects of B cell-activating factor on tumor immunity. Jci Insight. 5. PMID 32434989 DOI: 10.1172/Jci.Insight.136417 |
0.536 |
|
| 2020 |
Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nature Reviews. Clinical Oncology. PMID 32398706 DOI: 10.1038/S41571-020-0363-5 |
0.337 |
|
| 2020 |
Ho WJ, Danilova L, Lim SJ, Verma R, Xavier S, Leatherman JM, Sztein MB, Fertig EJ, Wang H, Jaffee E, Yarchoan M. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. Journal For Immunotherapy of Cancer. 8. PMID 32303615 DOI: 10.1136/Jitc-2019-000394 |
0.319 |
|
| 2020 |
Mardis ER, Ribas A, Hait WN, Jaffee EM, Foti M, Abate-Shen C, Albini A, Bernards R, Cruz-Correa MR, Flaherty KT, Greenberg PD, June CH, Knudsen KE, Liu ET, Mills GB, et al. AACR calls on congress to take immediate action against COVID-19 and protect patients with cancer during the pandemic Cancer Discovery. 10: 771-774. PMID 32295764 DOI: 10.1158/2159-8290.Cd-20-0449 |
0.337 |
|
| 2020 |
Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, ... ... Jaffee EM, et al. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-mesothelin (CRS-207) With or Without Nivolumab in Patients with Pancreatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32273276 DOI: 10.1158/1078-0432.Ccr-19-3978 |
0.478 |
|
| 2020 |
Korangath P, Barnett JD, Sharma A, Henderson ET, Stewart J, Yu SH, Kandala SK, Yang CT, Caserto JS, Hedayati M, Armstrong TD, Jaffee E, Gruettner C, Zhou XC, Fu W, et al. Nanoparticle interactions with immune cells dominate tumor retention and induce T cell-mediated tumor suppression in models of breast cancer. Science Advances. 6: eaay1601. PMID 32232146 DOI: 10.1126/Sciadv.Aay1601 |
0.468 |
|
| 2020 |
Wang H, Sové RJ, Jafarnejad M, Rahmeh S, Jaffee EM, Stearns V, Torres ETR, Connolly RM, Popel AS. Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. Frontiers in Bioengineering and Biotechnology. 8: 141. PMID 32158754 DOI: 10.3389/Fbioe.2020.00141 |
0.501 |
|
| 2020 |
Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. The Lancet. Oncology. 21: e135-e145. PMID 32135117 DOI: 10.1016/S1470-2045(19)30795-8 |
0.365 |
|
| 2020 |
Nair N, Chen SY, Lemmens E, Chang S, Le DT, Jaffee EM, Murphy A, Whiting C, Müller T, Brockstedt DG. SINGLE-CELL IMMUNE COMPETENCY SIGNATURES ASSOCIATE WITH SURVIVAL IN PHASE 2 GVAX AND CRS-207 RANDOMIZED STUDIES IN METASTATIC PANCREATIC CANCER PATIENTS. Cancer Immunology Research. PMID 32132105 DOI: 10.1158/2326-6066.Cir-19-0650 |
0.433 |
|
| 2020 |
Suresh R, Barakat DJ, Barberi T, Zheng L, Jaffee E, Pienta KJ, Friedman AD. NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma. Journal For Immunotherapy of Cancer. 8. PMID 31940589 DOI: 10.1136/Jitc-2019-000244 |
0.453 |
|
| 2020 |
Bever KM, Wang H, Durham JN, Petrie S, Hoare J, Wilt C, Sharfman WH, Azad NS, Laheru DA, Anders RA, Pardoll DM, Topalian SL, Jaffee EM, Le DT. Phase II study of nivolumab and relatlimab in advanced mismatch repair deficient (dMMR) cancers resistant to prior PD-(L)1 inhibition. Journal of Clinical Oncology. 38: TPS839-TPS839. DOI: 10.1200/Jco.2020.38.4_Suppl.Tps839 |
0.407 |
|
| 2020 |
Bever KM, Borazanci EH, Thompson E, Wu A, Durham JN, Liu M, Wilt C, Fu W, Leal JP, De Jesus-Acosta A, Wang H, Cosgrove D, Zheng L, Laheru DA, Von Hoff DD, ... Jaffee EM, et al. An exploratory study of metformin (Met) with or without rapamycin (Rapa) as maintenance therapy after induction chemotherapy in patients (Pts) with metastatic pancreatic adenocarcinoma (PDA). Journal of Clinical Oncology. 38: 700-700. DOI: 10.1200/Jco.2020.38.4_Suppl.700 |
0.354 |
|
| 2020 |
Jakubowski C, Thompson ED, Wang H, Walker R, Jaffee EM, Azad NS. A phase II trial of PD-1 inhibition with INCMGA00012 in patients with previously treated unresectable or metastatic adenosquamous pancreatic cancer. Journal of Clinical Oncology. 38: TPS4662-TPS4662. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps4662 |
0.47 |
|
| 2020 |
Jakubowski C, Collins NB, Sugar EA, Berg M, Cao H, Giannakis M, Jaffee EM, Azad NS. A phase I/II study of PI3Kinase inhibition with copanlisib combined with the anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in MSS colorectal cancer. Journal of Clinical Oncology. 38: TPS4114-TPS4114. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps4114 |
0.45 |
|
| 2020 |
Roussos Torres ET, Sidiropoulos DN, Davis-Marcisak E, Kagohara LT, Connolly RM, Stearns V, Jaffee EM, Fertig EJ. Characterization of the immune tumor microenvironment of HER2-positive breast cancer following treatment with entinostat and immune checkpoint inhibition. Journal of Clinical Oncology. 38: e15061-e15061. DOI: 10.1200/Jco.2020.38.15_Suppl.E15061 |
0.554 |
|
| 2020 |
Suresh RR, Barakat DJ, Barberi T, Zheng L, Jaffee EM, Pienta KJ, Friedman AD. Abstract B68: NF-kB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-B68 |
0.461 |
|
| 2020 |
Marshall CH, Yegnasubramanian S, Wang H, Durham J, Wang T, Damico R, D'Alessio FR, Sidhaye VK, Pekosz A, Mankowski JL, Klein SL, Murli S, Jaffee EM, Denmeade SR. Abstract IA09: A phase II trial to promote recovery from COVID-19 with endocrine therapy Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Covid-19-Ia09 |
0.301 |
|
| 2020 |
Torres ETR, Kagohara LT, Davis E, Rafie C, Christmas B, Zhu Q, Wang C, Lim D, Anders R, Fertig E, Chung V, Lorusso P, Brufsky A, Jaffee EM, Stearns V, et al. Abstract P5-04-06: Reprogramming the suppressive tumor microenvironment of breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P5-04-06 |
0.377 |
|
| 2020 |
Chan IS, Knútsdoóttir H, Ramakrishnan G, Padmanaban V, Bader JS, Jaffee EM, Ewald AJ. Abstract P3-01-01: A dual role of natural killer cells in breast cancer metastasis Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-01-01 |
0.454 |
|
| 2020 |
Sidiropoulos DN, Davis-Marcisak E, Rafie C, Kagohara LT, Sharma G, Connolly RM, Stearns V, Yegnasubramanian S, Jaffee EM, Fertig EJ, Torres ETR. Abstract 1555: Single cell level treatment-specific characterization of HER2+ breast cancers treated with immune checkpoint inhibitors and entinostat Tumor Biology. DOI: 10.1158/1538-7445.Am2020-1555 |
0.373 |
|
| 2019 |
Yarchoan M, Huang CY, Zhu Q, Ferguson AK, Durham JN, Anders RA, Thompson ED, Rozich NS, Thomas DL, Nauroth JM, Rodriguez C, Osipov A, De Jesus-Acosta A, Le DT, Murphy AG, ... ... Jaffee EM, et al. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Medicine. PMID 31876399 DOI: 10.1002/Cam4.2763 |
0.539 |
|
| 2019 |
Ho WJ, Yarchoan M, Charmsaz S, Munday RM, Danilova L, Sztein MB, Fertig EJ, Jaffee EM. Multi-panel mass cytometry reveals anti-PD1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes. Jci Insight. PMID 31855578 DOI: 10.1172/Jci.Insight.132286 |
0.437 |
|
| 2019 |
Ho WJ, Jaffee EM. Disrupting a converging metabolic target turns up the immunologic-heat in pancreatic tumors. The Journal of Clinical Investigation. PMID 31793910 DOI: 10.1172/Jci133685 |
0.427 |
|
| 2019 |
Stein JE, Lipson EJ, Cottrell TR, Forde PM, Anders RA, Cimino-Mathews A, Thompson ED, Allaf ME, Yarchoan M, Feliciano J, Wang H, Jaffee EM, Pardoll DM, Topalian SL, Taube JM. Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31672770 DOI: 10.1158/1078-0432.Ccr-19-2379 |
0.41 |
|
| 2019 |
Yarchoan M, Mohan AA, Dennison L, Vithayathil T, Ruggieri A, Lesinski GB, Armstrong TD, Azad NS, Jaffee EM. MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity. Plos One. 14: e0224600. PMID 31671149 DOI: 10.1371/Journal.Pone.0224600 |
0.488 |
|
| 2019 |
Llosa NJ, Luber B, Siegel N, Awan AH, Oke T, Zhu Q, Bartlett BR, Aulakh LK, Thompson ED, Jaffee EM, Durham JN, Sears CL, Le DT, Diaz LA, Pardoll DM, et al. IMMUNOPATHOLOGIC STRATIFICATION OF COLORECTAL CANCER FOR CHECKPOINT BLOCKADE IMMUNOTHERAPY. Cancer Immunology Research. PMID 31439614 DOI: 10.1158/2326-6066.Cir-18-0927 |
0.389 |
|
| 2019 |
Surcel A, Schiffhauer ES, Thomas DG, Zhu Q, DiNapoli KT, Herbig M, Otto O, West-Foyle H, Jacobi A, Kräter M, Plak K, Guck J, Jaffee EM, Iglesias PA, Anders RA, et al. Targeting mechanoresponsive proteins in pancreatic cancer: 4-hydroxyacetophenone blocks dissemination and invasion by activating MYH14. Cancer Research. PMID 31358530 DOI: 10.1158/0008-5472.Can-18-3131 |
0.421 |
|
| 2019 |
Davis-Marcisak EF, Sherman TD, Orugunta P, Stein-O'Brien GL, Puram SV, Roussos Torres ET, Hopkins AC, Jaffee EM, Favorov AV, Afsari B, Goff LA, Fertig EJ. Differential variation analysis enables detection of tumor heterogeneity using single-cell RNA-sequencing data. Cancer Research. PMID 31337651 DOI: 10.1158/0008-5472.Can-18-3882 |
0.489 |
|
| 2019 |
Hassan R, Alley E, Kindler H, Antonia SJ, Jahan TM, Honarmand S, Nair N, Whiting C, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, ... ... Jaffee EM, et al. Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31263030 DOI: 10.1158/1078-0432.Ccr-19-0070 |
0.469 |
|
| 2019 |
Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, Sivajothi S, Armstrong TD, Engle DD, Yu KH, Hao Y, ... ... Jaffee EM, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discovery. PMID 31197017 DOI: 10.1158/2159-8290.Cd-19-0094 |
0.506 |
|
| 2019 |
Blair AB, Kim V, Muth S, Saung MT, Lokker N, Blouw B, Armstrong TD, Jaffee EM, Tsujikawa T, Coussens LM, He J, Burkhart RA, Wolfgang CL, Zheng L. Dissecting the stromal signaling and regulation of myeloid cells and memory effector T cells in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31186314 DOI: 10.1158/1078-0432.Ccr-18-4192 |
0.433 |
|
| 2019 |
Jurcak NR, Rucki AA, Muth S, Thompson E, Sharma R, Ding D, Zhu Q, Eshleman JR, Anders RA, Jaffee EM, Fujiwara K, Zheng L. Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice. Gastroenterology. PMID 31163177 DOI: 10.1053/J.Gastro.2019.05.065 |
0.336 |
|
| 2019 |
Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein PE, Morse MA, Zeh H, Weekes CD, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, ... ... Jaffee EM, et al. A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31126960 DOI: 10.1158/1078-0432.Ccr-18-2992 |
0.412 |
|
| 2019 |
Kim VM, Blair AB, Lauer P, Foley K, Che X, Soares K, Xia T, Muth ST, Kleponis J, Armstrong TD, Wolfgang CL, Jaffee EM, Brockstedt D, Zheng L. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. Journal For Immunotherapy of Cancer. 7: 132. PMID 31113479 DOI: 10.1186/S40425-019-0601-5 |
0.754 |
|
| 2019 |
Wu AA, Jaffee E, Lee V. Current Status of Immunotherapies for Treating Pancreatic Cancer. Current Oncology Reports. 21: 60. PMID 31101991 DOI: 10.1007/S11912-019-0811-5 |
0.334 |
|
| 2019 |
Danilova L, Ho WJ, Zhu Q, Vithayathil TT, De Jesus-Acosta A, Azad NS, Laheru DA, Fertig EJ, Anders R, Jaffee EM, Yarchoan M. Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunology Research. PMID 31043417 DOI: 10.1158/2326-6066.Cir-18-0822 |
0.43 |
|
| 2019 |
Zaidi N, Quezada SA, Kuroiwa JMY, Zhang L, Jaffee EM, Steinman RM, Wang B. Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4 effector T cell infiltration into murine pancreatic tumors. Annals of the New York Academy of Sciences. PMID 30945313 DOI: 10.1111/Nyas.14049 |
0.56 |
|
| 2019 |
Kim AK, Gani F, Layman AJ, Besharati S, Zhu Q, Succaria F, Engle EL, Bhaijee F, Goggins MB, Llosa NJ, Pawlik TM, Yarchoan M, Jaffee EM, Simons HC, Taube JM, et al. Multiple immune suppressive mechanisms in fibrolamellar carcinoma. Cancer Immunology Research. PMID 30902819 DOI: 10.1158/2326-6066.Cir-18-0499 |
0.411 |
|
| 2019 |
Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, Jaffee EM. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. Jci Insight. 4. PMID 30895946 DOI: 10.1172/Jci.Insight.126908 |
0.351 |
|
| 2019 |
Jin J, Krishnamachary B, Barnett JD, Chatterjee S, Chang D, Mironchik Y, Wildes F, Jaffee E, Nimmagadda S, Bhujwalla ZM. Human cancer cell membrane coated biomimetic nanoparticles reduce fibroblast-mediated invasion and metastasis, and induce T cells. Acs Applied Materials & Interfaces. PMID 30707559 DOI: 10.1021/Acsami.8B22309 |
0.386 |
|
| 2019 |
Ma HS, Poudel B, Roussos Torres ET, Sidhom JW, Robinson TM, Christmas BJ, Scott BA, Cruz KA, Woolman S, Wall VZ, Armstrong TD, Jaffee EM. A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of non-immunogenic tumors to allow T cell-mediated anticancer activity. Cancer Immunology Research. PMID 30642833 DOI: 10.1158/2326-6066.Cir-18-0061 |
0.56 |
|
| 2019 |
Zaidi N, Jaffee EM. Immune cells track hard-to-target brain tumours. Nature. 565: 170-171. PMID 30622348 DOI: 10.1038/D41586-018-07728-9 |
0.389 |
|
| 2019 |
Zaidi N, Jaffee EM. Immunotherapy transforms cancer treatment. The Journal of Clinical Investigation. 129: 46-47. PMID 30507614 DOI: 10.1172/Jci126046 |
0.301 |
|
| 2019 |
Murphy AG, Walker R, Lutz ER, Parkinson R, Ahuja N, Zheng L, Jaffee EM, Azad NS. Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer. Journal of Clinical Oncology. 37: 591-591. DOI: 10.1200/Jco.2019.37.4_Suppl.591 |
0.416 |
|
| 2019 |
Yarchoan M, Ferguson AK, Durham JN, Rozich N, Rodriguez C, Huang C, Browner IS, Jesus-Acosta AD, Le DT, Laheru D, Donehower RC, Jaffee EM, Zheng L, Azad NS. A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer. Journal of Clinical Oncology. 37: 563-563. DOI: 10.1200/Jco.2019.37.4_Suppl.563 |
0.515 |
|
| 2019 |
Osipov A, Popovic A, Hopkins A, Frampton GM, Albacker LA, Azad NS, Laheru DA, Zheng L, Jaffee EM, Yarchoan M. Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination. Journal of Clinical Oncology. 37: 2578-2578. DOI: 10.1200/Jco.2019.37.15_Suppl.2578 |
0.347 |
|
| 2019 |
Santa-Maria C, Wang C, Cimino-Mathews A, Roussos-Torres E, Connolly R, Wolff A, Jaffee E, Stearns V. Abstract OT3-02-03: IMMUNe mOdulation in early stage estrogen receptor positive breast cancer treated with neoADjuvant Avelumab, Palbociclib, and Tamoxifen: The ImmunoADAPT study (NCT03573648) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ot3-02-03 |
0.394 |
|
| 2019 |
Zaidi N, Soban M, Haider S, Chen F, Armstrong TD, Jaffee EM. Abstract LB-020: Neoantigen targeted vaccine converts pancreatic tumors into immune sensitive tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-020 |
0.488 |
|
| 2019 |
Popovic A, Sugar E, Ferguson A, Wilt B, Durham JN, Kamel IR, Kim A, Philosophe B, Anders RA, Jaffee EM, Laheru D, Weiss MJ, Yarchoan M. Abstract CT207: Feasibility of neoadjuvant cabozantinib plus nivolumab followed by definitive resection for patients with locally advanced hepatocellular carcinoma: A Phase Ib trial (NCT03299946) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct207 |
0.409 |
|
| 2019 |
Davis-Marcisak EF, Orugunta P, Stein-O'Brien G, Puram SV, Torres ER, Hopkins A, Jaffee EM, Favorov AV, Afsari B, Goff LA, Fertig EJ. Abstract 4697: Expression variation analysis for tumor heterogeneity in single-cell RNA-sequencing data Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4697 |
0.348 |
|
| 2019 |
Ho WJ, Danilova L, Zhu Q, Vithayathil T, Jesus-Acosta AD, Azad N, Laheru D, Fertig E, Anders R, Jaffee E, Yarchoan M. Abstract 3993: Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identifies an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3993 |
0.334 |
|
| 2019 |
Christmas BJ, Rafie CI, Jaffee EM, Torres ETR. Abstract 1529: STAT3 mediates epigenetic regulation of MDSCs in tumors Cancer Research. 79: 1529-1529. DOI: 10.1158/1538-7445.Sabcs18-1529 |
0.514 |
|
| 2019 |
Osipov A, Sugar E, Ferguson A, Durham J, Rodriguez C, Parkinson R, Sena L, Zheng L, Wolfgang C, Burkhart R, He J, Weiss M, Narang A, Laheru D, Azad N, ... Jaffee E, et al. Abstract CT164: A Phase II clinical trial of GVAX pancreas vaccine (with Cyclophosphamide) in combination with Nivolumab and Stereotactic Body Radiation Therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct164 |
0.483 |
|
| 2019 |
Pucsek AB, Armstrong TD, Jaffee EM. Abstract 581: Determining the influence of galectin-3 binding properties on its suppression of tumor antigen-specific CD8+ T cells Cancer Research. 79: 581-581. DOI: 10.1158/1538-7445.Am2019-581 |
0.513 |
|
| 2019 |
Torres ETR, Rafie C, Davis E, Kagohara LT, Fertig EJ, Jaffee EM. Abstract 5027: Sequencing the tumor microenvironment and myeloid derived suppressor cells to understand response to immunotherapy in primary HER2 positive breast cancer Cancer Research. 79: 5027-5027. DOI: 10.1158/1538-7445.Am2019-5027 |
0.514 |
|
| 2019 |
Wu AA, Tsujikawa T, Choe G, Beechwood T, Coussens LM, Durham JN, Jaffee EM, Le DT. Abstract 4491: Association of intratumoral immunologic profile with overall survival in metastatic pancreatic cancer patients treated with combination immunotherapy with or without PD-1 blockade Cancer Research. 79: 4491-4491. DOI: 10.1158/1538-7445.Am2019-4491 |
0.545 |
|
| 2019 |
Thomas DL, Murphy AG, Weiss MJ, He J, Makary MA, Burkhart RA, Wolfgang CL, Jaffee EM, Zheng L, Thompson ED. Abstract 3102A: Analysis of spatial relationships between infiltrating immune cells within the tumor microenvironment following combinatorial immunotherapy Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-3102A |
0.418 |
|
| 2019 |
Rafie C, Cruz K, Woolman S, Armstrong T, Jaffee E, Torres ER. Abstract 2352: Epigenetic modulation— unlocking the potential of checkpoint inhibition in advanced breast cancer Cancer Research. 79: 2352-2352. DOI: 10.1158/1538-7445.Am2019-2352 |
0.56 |
|
| 2019 |
Jurcak NR, Muth S, Fujiwara K, Rucki A, Foley K, Murphy A, Jaffee EM, Zheng L. Abstract 167: Semaphorin3D signaling in the invasion and metastasis of pancreatic ductal adenocarcinoma Cancer Research. 79: 167-167. DOI: 10.1158/1538-7445.Am2019-167 |
0.737 |
|
| 2019 |
Jurcak NR, Zarecki M, Lee F, Rozich N, Muth S, Jaffee E, Stienen S, Bailis J, Zheng L. Abstract 1561: Evaluation of mesothelin BiTE® antibody constructs in models of pancreatic ductal adenocarcinoma Cancer Research. 79: 1561-1561. DOI: 10.1158/1538-7445.Am2019-1561 |
0.539 |
|
| 2018 |
Luke JJ, Edwards R, Hedvat C, Pandya D, Ely S, Meier R, McDonald D, Harbison CT, Baxi V, Lee G, Szabo P, Garcia T, Bao R, Reilly TP, Jaffee E, et al. Characterization of the immune tumor microenvironment (TME) to inform personalized medicine with immuno-oncology (IO) combinations. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii403. PMID 32137011 DOI: 10.1093/Annonc/Mdy288.008 |
0.389 |
|
| 2018 |
Kumar D, Lisok A, Dahmane E, McCoy MD, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, et al. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. The Journal of Clinical Investigation. PMID 30457978 DOI: 10.1172/Jci122216 |
0.301 |
|
| 2018 |
Saung MT, Muth S, Ding D, Thomas DL, Blair AB, Tsujikawa T, Coussens L, Jaffee EM, Zheng L. Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. Journal For Immunotherapy of Cancer. 6: 118. PMID 30424804 DOI: 10.1186/S40425-018-0435-6 |
0.504 |
|
| 2018 |
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30395155 DOI: 10.1093/Annonc/Mdy495 |
0.403 |
|
| 2018 |
Christmas BJ, Rafie CI, Hopkins AC, Scott BA, Ma HS, Cruz KA, Woolman S, Armstrong TD, Connolly RM, Azad NA, Jaffee EM, Roussos Torres ET. Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunology Research. PMID 30341213 DOI: 10.1158/2326-6066.Cir-18-0070 |
0.558 |
|
| 2018 |
Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K, Woolman S, Vithayathil T, Glickman LH, Ndubaku CO, McWhirter SM, Dubensky TW, Armstrong TD, Jaffee EM, Zaidi N. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. Jci Insight. 3. PMID 30333318 DOI: 10.1172/Jci.Insight.122857 |
0.575 |
|
| 2018 |
Popovic A, Jaffee EM, Zaidi N. Emerging strategies for combination checkpoint modulators in cancer immunotherapy. The Journal of Clinical Investigation. 128: 3209-3218. PMID 30067248 DOI: 10.1172/Jci120775 |
0.562 |
|
| 2018 |
Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. Jci Insight. 3. PMID 29997287 DOI: 10.1172/Jci.Insight.122092 |
0.435 |
|
| 2018 |
Hopkins A, Jaffee E. Pancreatic cancer: Next-generation algorithms for neoantigen selection Nature Reviews Gastroenterology & Hepatology. 15: 135-136. PMID 29317775 DOI: 10.1038/Nrgastro.2017.184 |
0.316 |
|
| 2018 |
Baretti M, Durham JN, Walker R, Mitcheltree A, Christmas B, Cope L, Jaffee EM, Azad NS. Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. Journal of Clinical Oncology. 36: TPS4151-TPS4151. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps4151 |
0.407 |
|
| 2018 |
Melero Bermejo I, Jaffee EM, Davar D, Cardarelli J, Williams D, Phillips P, Carleton M, Zhou M, De Henau O, Monga M, Drake CG. Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer. Journal of Clinical Oncology. 36: TPS3109-TPS3109. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps3109 |
0.388 |
|
| 2018 |
Torres ER, Ma H, Christmas B, Armstrong T, Jaffee E. Abstract P1-08-01: Combination checkpoint inhibition and epigenetic modulation promotes tumor suppression and improves survival in Her2+ models of breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P1-08-01 |
0.554 |
|
| 2018 |
Wu AA, Tsujikawa T, Choe G, Beechwood T, Coussens LM, Durham JN, Jaffee EM, Le DT. Abstract 611: PD-1-based combination immunotherapy reinvigorates CD8+ T cells in metastatic pancreatic cancer patients with improved survival Cancer Research. 78: 611-611. DOI: 10.1158/1538-7445.Am2018-611 |
0.573 |
|
| 2018 |
Torres ETR, Rafie C, Ma H, Christmas B, Armstrong T, Jaffee EM. Abstract 4965: Entinostat transforms the suppressive tumor microenvironment of breast cancer and promotes survival and anti-responses when combined with checkpoint inhibition Cancer Research. 78: 4965-4965. DOI: 10.1158/1538-7445.Am2018-4965 |
0.549 |
|
| 2018 |
Popovic A, Chu NJ, Armstrong T, Jaffee EM. Abstract 3778: Combination immunotherapy intercepts murine pancreatic cancer progression Cancer Research. 78: 3778-3778. DOI: 10.1158/1538-7445.Am2018-3778 |
0.558 |
|
| 2018 |
Surcel A, Schiffhauer ES, Thomas DG, Zhu Q, DiNapoli K, Herbig M, Otto O, Guck J, Jaffee E, Iglesias PA, Anders RA, Robinson DN. Abstract 3154: Harnessing the adaptive potential of mechanoresponsive proteins to overwhelm pancreatic cancer dissemination and invasion Tumor Biology. DOI: 10.1158/1538-7445.Am2018-3154 |
0.332 |
|
| 2018 |
Jurcak NR, Fujiwara K, Rucki AA, Foley K, Murphy A, Muth S, Brittingham A, Jaffee EM, Zheng L. Abstract 3026: Role of AnnexinA2, Sema3D and PlexinD1 in mediating perineural invasion as a mechanism of metastasis in pancreatic ductal adenocarcinoma Cancer Research. 78: 3026-3026. DOI: 10.1158/1538-7445.Am2018-3026 |
0.744 |
|
| 2018 |
Christmas B, Scott B, Armstrong T, Azad N, Jaffee E. Abstract 1746: Epigenetic modulation of the tumor microenvironment enhances immune checkpoint efficacy in a murine model of pancreatic cancer Cancer Research. 78: 1746-1746. DOI: 10.1158/1538-7445.Am2018-1746 |
0.547 |
|
| 2017 |
Diehl A, Yarchoan M, Hopkins A, Jaffee E, Grossman SA. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget. 8: 114268-114280. PMID 29371985 DOI: 10.18632/Oncotarget.23217 |
0.388 |
|
| 2017 |
Murphy AG, Foley K, Rucki AA, Xia T, Jaffee EM, Huang CY, Zheng L. Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer. Oncotarget. 8: 106405-106414. PMID 29290958 DOI: 10.18632/Oncotarget.22433 |
0.717 |
|
| 2017 |
Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, et al. Future cancer research priorities in the USA: a Lancet Oncology Commission. The Lancet. Oncology. 18: e653-e706. PMID 29208398 DOI: 10.1016/S1470-2045(17)30698-8 |
0.33 |
|
| 2017 |
Emens LA, Bruno R, Rubin EH, Jaffee EM, McKee AE. Report on the Third FDA-AACR Oncology Dose-Finding Workshop. Cancer Immunology Research. 5: 1058-1061. PMID 29196440 DOI: 10.1158/2326-6066.Cir-17-0590 |
0.323 |
|
| 2017 |
Rao AD, Liu Y, von Eyben R, Hsu CC, Hu C, Rosati LM, Parekh A, Ng K, Hacker-Prietz A, Zheng L, Pawlik TM, Laheru DA, Jaffee EM, Weiss MJ, Le DT, et al. Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics. PMID 29157747 DOI: 10.1016/J.Ijrobp.2017.10.001 |
0.34 |
|
| 2017 |
Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, et al. A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunology Research. PMID 29038296 DOI: 10.1158/2326-6066.Cir-17-0375 |
0.468 |
|
| 2017 |
Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW. Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer. Journal For Immunotherapy of Cancer. 5: 77. PMID 28923102 DOI: 10.1186/S40425-017-0278-6 |
0.368 |
|
| 2017 |
Rucki AA, Xiao Q, Muth S, Chen J, Che X, Kleponis J, Sharma R, Anders RA, Jaffee EM, Zheng L. Dual inhibition of Hedgehog and c-Met pathways for pancreatic cancer treatment. Molecular Cancer Therapeutics. PMID 28864680 DOI: 10.1158/1535-7163.Mct-16-0452 |
0.398 |
|
| 2017 |
Shields AF, Jacobs P, Sznol M, Graham MM, Germain R, Lum L, Jaffee E, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung D, Wu AM, Sharon E, Shankar LK. Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28818991 DOI: 10.2967/Jnumed.117.195610 |
0.317 |
|
| 2017 |
Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, Kanne DB, Jaffee EM, Dubensky TW, Emens LA. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunology Research. PMID 28483787 DOI: 10.1158/2326-6066.Cir-16-0284 |
0.509 |
|
| 2017 |
Yarchoan M, Myzak MC, Johnson Iii BA, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M. Olaparib in combination with irinotecan, cisplatin, and mitomycin c in patients with advanced pancreatic cancer. Oncotarget. PMID 28454122 DOI: 10.18632/Oncotarget.17237 |
0.34 |
|
| 2017 |
Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G, Sauer D, El Rassi E, Clayburgh DR, Kulesz-Martin MF, Lutz ER, Zheng L, ... Jaffee EM, et al. Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. Cell Reports. 19: 203-217. PMID 28380359 DOI: 10.1016/J.Celrep.2017.03.037 |
0.458 |
|
| 2017 |
Johnson BA, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for Increasing Pancreatic Tumor Immunogenicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 1656-1669. PMID 28373364 DOI: 10.1158/1078-0432.Ccr-16-2318 |
0.455 |
|
| 2017 |
Yarchoan M, Johnson BA, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nature Reviews. Cancer. PMID 28233802 DOI: 10.1038/Nrc.2016.154 |
0.377 |
|
| 2017 |
Foley K, Muth S, Jaffee E, Zheng L. Hedgehog signaling stimulates Tenascin C to promote invasion of pancreatic ductal adenocarcinoma cells through Annexin A2. Cell Adhesion & Migration. 0. PMID 28152318 DOI: 10.1080/19336918.2016.1259057 |
0.73 |
|
| 2017 |
Le DT, Ko AH, Wainberg ZA, Picozzi VJ, Kindler HL, Wang-Gillam A, Oberstein PE, Morse M, Zeh H, Weekes CD, Reid TR, Murphy A, McDougall K, Whiting CC, Nair N, ... ... Jaffee EM, et al. Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Journal of Clinical Oncology. 35: 345-345. DOI: 10.1200/Jco.2017.35.4_Suppl.345 |
0.435 |
|
| 2017 |
Lee V, Rodriguez C, Shupe E, Chen L, Parkinson R, Durham JN, Sugar E, Wilt C, McIntyre KR, Hacker-Prietz A, Weiss MJ, He J, Wolfgang CL, De Jesus-Acosta A, Le DT, ... ... Jaffee EM, et al. Phase II study of GM-CSF secreting allogeneic pancreatic cancer vaccine (GVAX) with PD-1 blockade antibody and stereotactic body radiation therapy (SBRT) for locally advanced pancreas cancer (LAPC). Journal of Clinical Oncology. 35: TPS4154-TPS4154. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps4154 |
0.474 |
|
| 2017 |
Diehl A, Yarchoan M, Yang T, Scott B, Johnson BA, Hopkins A, Azad NS, Jaffee EM, Grossman SA. Relationship of lymphocyte and eosinophil counts and immune-related adverse events in recipients of programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis. Journal of Clinical Oncology. 35: e14586-e14586. DOI: 10.1200/Jco.2017.35.15_Suppl.E14586 |
0.371 |
|
| 2017 |
Yarchoan M, Diehl A, Johnson BA, Scott B, Hopkins A, Azad NS, Jaffee EM, Grossman SA. Relationship between lymphopenia and objective response rate with programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis. Journal of Clinical Oncology. 35: e14512-e14512. DOI: 10.1200/Jco.2017.35.15_Suppl.E14512 |
0.387 |
|
| 2017 |
Torres ER, Ma H, Armstrong T, Connolly R, Stearns V, Jaffee E. Abstract P2-04-11: Promotion of immunogenicity using epigenetic modulation and immune checkpoint inhibition in mouse models of breast cancer Cancer Research. 77: 3667-3667. DOI: 10.1158/1538-7445.Sabcs16-P2-04-11 |
0.551 |
|
| 2017 |
Scott BA, Armstrong T, Willingham S, McCaffery I, Jaffee EM. Abstract 5579: Strategic inhibition of adenosine A2A receptor (A2AR) by CPI-444 improves CD8+:Treg ratios and enhances T-cell killing of a HER-2/neu expressing murine tumor Cancer Research. 77: 5579-5579. DOI: 10.1158/1538-7445.Am2017-5579 |
0.558 |
|
| 2017 |
Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski B, Kanne DB, Jaffee EM, Dubensky TW, Emens LA. Abstract 2993: STING signaling in breast tumor microenvironment modulates immune checkpoint blockade efficacy in the neu-N mouse model of breast cancer Cancer Research. 77: 2993-2993. DOI: 10.1158/1538-7445.Am2017-2993 |
0.557 |
|
| 2017 |
Ma HS, Torres ER, Poudel B, Robinson T, Christmas B, Cruz K, Woolman S, Rafie C, Scott B, Wall V, Armstrong T, Jaffee E. Abstract 4936: Combination CD40 agonist and PD-1 antagonist antibody therapy enhances vaccine induced T cell responses in non-immunogenic cancers Cancer Research. 77: 2613-2613. DOI: 10.1158/1538-7445.Am2017-2613 |
0.575 |
|
| 2017 |
Kinkead H, Lutz E, Dubensky TW, Jaffee E. Abstract 1695: Exploiting the pancreatic cancer mutome for immune interception Cancer Research. 77: 1695-1695. DOI: 10.1158/1538-7445.Am2017-1695 |
0.511 |
|
| 2017 |
Christmas B, Scott B, Armstrong T, Azad N, Jaffee E. Abstract 1686: Epigenetic modulation of the tumor microenvironment enhances vaccine induced T cell responses in a murine model of pancreatic cancer Cancer Research. 77: 1686-1686. DOI: 10.1158/1538-7445.Am2017-1686 |
0.609 |
|
| 2017 |
Rosati LM, Torto D, Hacker-Prietz A, Narang AK, Fishman EK, Hruban RH, Klein AP, Jaffee EM, Weiss MJ, Wolfgang CL, Laheru DA, Herman JM. (P028) Patient Retention After Initial Consultation Results in Extended Survival in Pancreatic Cancer International Journal of Radiation Oncology*Biology*Physics. 98: E22-E23. DOI: 10.1016/J.Ijrobp.2017.02.123 |
0.362 |
|
| 2016 |
Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Mesothelin Immunotherapy for Cancer: Ready for Prime Time? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4171-4179. PMID 27863199 DOI: 10.1200/Jco.2016.68.3672 |
0.502 |
|
| 2016 |
Rucki AA, Foley K, Zhang P, Xiao Q, Kleponis J, Wu A, Sharma R, Mo G, Liu A, Van Eyk J, Jaffee EM, Zheng L. Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Research. PMID 27821486 DOI: 10.1158/0008-5472.Can-16-1383 |
0.698 |
|
| 2016 |
Rao AD, Liu Y, Hsu CC, Parekh A, Rosati LM, Ng K, Hacker-Prietz A, Zheng L, Pawlik TM, Laheru DA, Jaffee EM, Weiss MJ, Le DT, Hruban RH, De Jesus-Acosta A, et al. Multiplex Proximal Ligation Assay Identifies Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics. 96: E597-E598. PMID 27675116 DOI: 10.1016/J.Ijrobp.2016.06.2126 |
0.337 |
|
| 2016 |
Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM. Leveraging premalignant biology for immune-based cancer prevention. Proceedings of the National Academy of Sciences of the United States of America. PMID 27638202 DOI: 10.1073/Pnas.1608077113 |
0.421 |
|
| 2016 |
Singer DS, Jacks T, Jaffee E. A U.S. "Cancer Moonshot" to accelerate cancer research. Science (New York, N.Y.). 353: 1105-6. PMID 27605537 DOI: 10.1126/Science.Aai7862 |
0.315 |
|
| 2016 |
Ladle BH, Li KP, Phillips MJ, Pucsek AB, Haile A, Powell JD, Jaffee EM, Hildeman DA, Gamper CJ. De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8+ T-cell fate decisions following activation. Proceedings of the National Academy of Sciences of the United States of America. PMID 27582468 DOI: 10.1073/Pnas.1524490113 |
0.787 |
|
| 2016 |
Xiao Q, Zhou D, Rucki AA, Williams JK, Zhou J, Mo G, Murphy A, Fujiwara K, Kleponis J, Salman B, Wolfgang CL, Anders RA, Zheng S, Jaffee EM, Zheng L. Cancer associated fibroblasts in pancreatic cancer are reprogrammed by tumor-induced alterations in genomic DNA methylation. Cancer Research. PMID 27496707 DOI: 10.1158/0008-5472.Can-15-3264 |
0.39 |
|
| 2016 |
Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, Hacker-Prietz A, Assadi RK, Saeed AM, Pawlik TM, Jaffee EM, Laheru DA, Tran PT, Weiss MJ, Wolfgang CL, et al. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer. International Journal of Radiation Oncology, Biology, Physics. 94: 571-9. PMID 26867885 DOI: 10.1016/J.Ijrobp.2015.11.026 |
0.347 |
|
| 2016 |
Jhaveri DT, Kim MS, Thompson ED, Huang L, Sharma R, Klein AP, Zheng L, Le DT, Laheru DA, Pandey A, Jaffee EM, Anders RA. Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer. Cancer Immunology Research. PMID 26842750 DOI: 10.1158/2326-6066.Cir-15-0200-T |
0.465 |
|
| 2016 |
Le DT, Crocenzi TS, Uram JN, Lutz ER, Laheru D, Sugar EA, Vonderheide RH, Fisher GA, Ko AH, Murphy AL, McDougall K, Ferber S, Brockstedt DG, Jaffee EM. Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). Journal of Clinical Oncology. 34: TPS486-TPS486. DOI: 10.1200/Jco.2016.34.4_Suppl.Tps486 |
0.811 |
|
| 2016 |
Le DT, Whiting CC, Lutz ER, Nair N, Engstrom A, Lemmens E, Tagliaferri MC, Murphy AL, Brockstedt DG, Jaffee EM. Clinical and immune characteristics of rapid dropout and long-term survival in a phase II safety and efficacy study of combination CRS-207/GVAX immunotherapy in pancreatic cancer. Journal of Clinical Oncology. 34: 459-459. DOI: 10.1200/Jco.2016.34.4_Suppl.459 |
0.451 |
|
| 2016 |
Murphy AG, White S, Walker R, Lutz ER, Ahuja N, Zheng L, Jaffee EM, Azad NS. Epigenetic priming prior to pembrolizumab in microsatellite-stable (MSS) advanced colorectal cancer. Journal of Clinical Oncology. 34: TPS3626-TPS3626. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps3626 |
0.428 |
|
| 2016 |
Jaffee EM. Abstract IA26: Combinatorial immunotherapies with the potential to reverse the carcinogenesis process Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Ia26 |
0.548 |
|
| 2016 |
Jaffee EM. Abstract IA16: Tipping the balance from a procarcinogenic to an antitumor microenvironment in pancreatic cancers Cancer Research. 76. DOI: 10.1158/1538-7445.Tme16-Ia16 |
0.564 |
|
| 2016 |
Scott BA, Armstrong T, Jaffee EM. Abstract 320: Inhibition of adenosine A2A receptor (A2AR) by CPI-444 enhances CD8+ T cell killing of a HER-2/neu expressing murine tumor Cancer Research. 76: 320-320. DOI: 10.1158/1538-7445.Am2016-320 |
0.593 |
|
| 2016 |
Kim V, Foley K, Soares K, Rucki A, Lauer P, Brockstedt D, Wolfgang C, Jaffee E, Zheng L. Sequential treatment with a listeria-based vaccine and PD-1 blockade antibody improves survival in a murine model of pancreatic ductal adenocarcinoma Hpb. 18: e45-e46. DOI: 10.1016/J.Hpb.2016.02.113 |
0.697 |
|
| 2015 |
Foley K, Kim V, Jaffee E, Zheng L. Current progress in immunotherapy for pancreatic cancer. Cancer Letters. PMID 26723878 DOI: 10.1016/J.Canlet.2015.12.020 |
0.783 |
|
| 2015 |
Soares KC, Rucki AA, Kim V, Foley K, Solt S, Wolfgang CL, Jaffee EM, Zheng L. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. Oncotarget. PMID 26515728 DOI: 10.18632/Oncotarget.5656 |
0.762 |
|
| 2015 |
Foley K, Rucki AA, Xiao Q, Zhou D, Leubner A, Mo G, Kleponis J, Wu AA, Sharma R, Jiang Q, Anders RA, Iacobuzio-Donahue CA, Hajjar KA, Maitra A, Jaffee EM, et al. Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Science Signaling. 8: ra77. PMID 26243191 DOI: 10.1126/Scisignal.Aaa5823 |
0.734 |
|
| 2015 |
Byrne KT, Vonderheide RH, Jaffee EM, Armstrong TD. Special Conference on Tumor Immunology and Immunotherapy: A New Chapter. Cancer Immunology Research. PMID 25968457 DOI: 10.1158/2326-6066.Cir-15-0106 |
0.513 |
|
| 2015 |
Wang J, Reiss KA, Khatri R, Jaffee E, Laheru D. Immune Therapy in GI Malignancies: A Review. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1745-1753. PMID 25918295 DOI: 10.1200/Jco.2015.60.7879 |
0.455 |
|
| 2015 |
Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, Jaffee E. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer Immunology Research. 3: 412-23. PMID 25691328 DOI: 10.1158/2326-6066.Cir-14-0150 |
0.489 |
|
| 2015 |
Chu NJ, Armstrong TD, Jaffee EM. Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1549-57. PMID 25623216 DOI: 10.1158/1078-0432.Ccr-14-1186 |
0.448 |
|
| 2015 |
Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, ... ... Jaffee EM, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1325-33. PMID 25584002 DOI: 10.1200/Jco.2014.57.4244 |
0.821 |
|
| 2015 |
Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L, Yao S, Anders RA, Laheru D, Wolfgang CL, Edil BH, ... ... Jaffee EM, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. Journal of Immunotherapy (Hagerstown, Md. : 1997). 38: 1-11. PMID 25415283 DOI: 10.1097/Cji.0000000000000062 |
0.452 |
|
| 2015 |
Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. Hpb : the Official Journal of the International Hepato Pancreato Biliary Association. 17: 292-8. PMID 25250696 DOI: 10.1111/Hpb.12334 |
0.393 |
|
| 2015 |
De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, et al. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. International Journal of Cancer. 136: 127-37. PMID 24832153 DOI: 10.1002/Ijc.28973 |
0.786 |
|
| 2015 |
Le DT, Wang-Gillam A, Picozzi VJ, Crocenzi TS, Morse M, Zeh H, Fine RL, Murphy A, Skoble J, Lemmens E, Ferber S, Rosen A, Grous JJ, Dubensky T, Brockstedt DG, ... Jaffee EM, et al. A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study) F1000research. 6. DOI: 10.7490/F1000Research.1097494.1 |
0.386 |
|
| 2015 |
Le DT, Wang-Gillam A, Picozzi VJ, Crocenzi TS, Morse M, Zeh H, Fine RL, Murphy A, Skoble J, Lemmens E, Ferber S, Rosen A, Grous JJ, Dubensky T, Brockstedt DG, ... ... Jaffee EM, et al. A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Journal of Clinical Oncology. 33: TPS489-TPS489. DOI: 10.1200/Jco.2015.33.3_Suppl.Tps489 |
0.498 |
|
| 2015 |
Whiting C, Lutz E, Nair N, Chang S, Lemmens E, Chen SY, Solt S, Ferber S, Maecker H, Murphy A, Brockstedt DG, Jaffee EM, Le DT. Phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer: Clinical update on long term survival and biomarker correlates to overall survival. Journal of Clinical Oncology. 33: 261-261. DOI: 10.1200/Jco.2015.33.3_Suppl.261 |
0.462 |
|
| 2015 |
Murphy A, Kleponis J, Rucki A, Jaffee EM, Zheng L, Foley K. Targeting Sema3D in pancreatic cancer: A novel therapeutic strategy. Journal of Clinical Oncology. 33: 4129-4129. DOI: 10.1200/Jco.2015.33.15_Suppl.4129 |
0.691 |
|
| 2015 |
Wang JS, Sausen M, Parpart-Li S, Murphy DM, Velculescu VE, Wood LD, Solt-Linville S, Sugar E, Bartlett B, Blair C, Dauses T, Jaffee EM, Hruban RH, Laheru D, Diaz LA. Circulating tumor DNA (ctDNA) as a prognostic marker for recurrence in resected pancreas cancer. Journal of Clinical Oncology. 33: 11025-11025. DOI: 10.1200/Jco.2015.33.15_Suppl.11025 |
0.41 |
|
| 2015 |
Foote J, Leatherman JM, Amstrong TD, Ojalvo L, Kanne D, Jaffee EM, Dubensky T, Emens L. Direct activation of STING in the tumor microenvironment partially overcomes immune tolerance in neu-N transgenic mice Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P356 |
0.493 |
|
| 2015 |
Nair N, Lemmens E, Enstrom A, Chen S, Chang S, Le D, Jaffee EM, Maecker H, Murphy AL, Brockstedt DG, Whiting C. Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P102 |
0.448 |
|
| 2015 |
Jaffee EM. Abstract PL04-03: Fatal Attraction: A new story featuring the immune system and pancreatic cancer Cancer Research. 72. DOI: 10.1158/1538-7445.Am2015-Pl04-03 |
0.542 |
|
| 2015 |
Sansal-Castellano I, Carlson M, Armstrong T, Reznik G, Siedlecki J, Kane J, Dostalova Z, Miao H, Jaffee E, Rubin-Bejerano I. Abstract 4297: mAbXcite: A novel immunotherapy platform that initiates a robust anti-cancer immune response by recruiting and activating neutrophils Cancer Research. 75: 4297-4297. DOI: 10.1158/1538-7445.Am2015-4297 |
0.51 |
|
| 2015 |
Herman J, Parkinson R, Onners B, Rao A, Zheng L, Le D, De Jesus-Acosta A, Lutz E, Hruban R, Hirose K, Fishman E, Weiss M, Hacker-Prietz A, Pawlik T, Cameron J, ... ... Jaffee E, et al. Preliminary Results of a Pilot Study Evaluating An Allogeneic GM-CSF Pancreatic Tumor Cell Vaccine (GVAX) and Cytoxan (Cy) With Stereotactic Body Radiation Therapy (SBRT) and Folfirinox (FFX) in Patients With Resected Pancreatic Adenocarcinoma International Journal of Radiation Oncology*Biology*Physics. 93: S154. DOI: 10.1016/J.Ijrobp.2015.07.367 |
0.409 |
|
| 2015 |
Rao A, Parkinson R, Onners B, Zheng L, Le D, Lutz E, De Jesus-Acosta A, Hruban R, Hirose K, Fishman E, Weiss M, Hacker-Prietz A, Pawlik T, Cameron J, Wolfgang C, ... Jaffee E, et al. Dosimetric Correlations with Toxicity in the First Experience Validating Adjuvant Fractionated Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer International Journal of Radiation Oncology*Biology*Physics. 93: E183. DOI: 10.1016/J.Ijrobp.2015.07.1016 |
0.323 |
|
| 2014 |
Lutz ER, Kinkead H, Jaffee EM, Zheng L. Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. Oncoimmunology. 3: e962401. PMID 25941589 DOI: 10.4161/21624011.2014.962401 |
0.488 |
|
| 2014 |
Jhaveri DT, Zheng L, Jaffee EM. Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. Seminars in Oncology. 41: 559-75. PMID 25440603 DOI: 10.1053/J.Seminoncol.2014.07.001 |
0.399 |
|
| 2014 |
Soares KC, Foley K, Olino K, Leubner A, Mayo SC, Jain A, Jaffee E, Schulick RD, Yoshimura K, Edil B, Zheng L. A preclinical murine model of hepatic metastases. Journal of Visualized Experiments : Jove. 51677. PMID 25285458 DOI: 10.3791/51677 |
0.72 |
|
| 2014 |
Smit MA, Jaffee EM, Lutz ER. Cancer immunoprevention--the next frontier. Cancer Prevention Research (Philadelphia, Pa.). 7: 1072-80. PMID 25245763 DOI: 10.1158/1940-6207.Capr-14-0178 |
0.405 |
|
| 2014 |
Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, Daphtary MM, Garrett-Mayer E, Davidson NE, Hirt K, Berg M, Uram JN, Dauses T, Fetting J, Duus EM, ... ... Jaffee EM, et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunology Research. 2: 949-61. PMID 25116755 DOI: 10.1158/2326-6066.Cir-14-0058 |
0.802 |
|
| 2014 |
Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM, Aust D, Grützmann R, Romero M, Totpal K, Neve RM, ... ... Jaffee EM, et al. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. The Journal of Pathology. 234: 502-13. PMID 25074413 DOI: 10.1002/Path.4412 |
0.361 |
|
| 2014 |
Ahmed MM, Guha C, Hodge JW, Jaffee E. Immunobiology of radiotherapy: new paradigms. Radiation Research. 182: 123-5. PMID 25036983 DOI: 10.1667/Rr13849.1 |
0.531 |
|
| 2014 |
Zheng L, Edil BH, Soares KC, El-Shami K, Uram JN, Judkins C, Zhang Z, Onners B, Laheru D, Pardoll D, Jaffee EM, Schulick RD. A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer. Annals of Surgical Oncology. 21: 3931-7. PMID 24943235 DOI: 10.1245/S10434-014-3844-X |
0.802 |
|
| 2014 |
Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, Solt S, Dorman A, Wamwea A, Yager A, Laheru D, Wolfgang CL, Wang J, Hruban RH, Anders RA, ... Jaffee EM, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunology Research. 2: 616-31. PMID 24942756 DOI: 10.1158/2326-6066.Cir-14-0027 |
0.56 |
|
| 2014 |
McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H, Jaffee EM, Drake CG, Housseau F, Maitra A, Kolls JK, et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell. 25: 621-37. PMID 24823639 DOI: 10.1016/J.Ccr.2014.03.014 |
0.31 |
|
| 2014 |
Lutz ER, Jaffee EM. Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy? Cancer Immunology Research. 2: 518-21. PMID 24795140 DOI: 10.1158/2326-6066.Cir-14-0041 |
0.402 |
|
| 2014 |
Black CM, Armstrong TD, Jaffee EM. Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunology Research. 2: 307-19. PMID 24764578 DOI: 10.1158/2326-6066.Cir-13-0145 |
0.84 |
|
| 2014 |
Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW, Hassan R, Armstrong TD, Jaffee EM. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology. 146: 1784-94.e6. PMID 24607504 DOI: 10.1053/J.Gastro.2014.02.055 |
0.497 |
|
| 2014 |
Kojima M, Murata S, Mekata E, Takebayashi K, Jaffee EM, Tani T. Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine. Journal of Immunotherapy (Hagerstown, Md. : 1997). 37: 147-54. PMID 24598447 DOI: 10.1097/Cji.0000000000000025 |
0.496 |
|
| 2014 |
Jaffee EM. Methods for retrovirus-mediated gene transfer to tumor cells. Methods in Molecular Medicine. 7: 307-27. PMID 24493436 DOI: 10.1385/0-89603-484-4:307 |
0.43 |
|
| 2014 |
Wang-Gillam A, Picozzi V, Crocenzi T, Morse M, Zeh H, Fine RL, Murphy A, Skoble J, Lemmens E, Ferber S, Rosen A, Grous J, Dubensky T, Brockstedt D, Jaffee E, et al. A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone... Journal For Immunotherapy of Cancer. 2: 68. DOI: 10.7916/D8X63Kk8 |
0.489 |
|
| 2014 |
Le DT, Wang-Gillam A, Picozzi, Jr V, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Laheru D, Murphy A, ... ... Jaffee EM, et al. A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results. Journal of Clinical Oncology. 32: 177-177. DOI: 10.1200/Jco.2014.32.3_Suppl.177 |
0.763 |
|
| 2014 |
Patel RK, Ko AH, Onners B, Uram JN, Parkinson R, Sugar E, Lutz E, Zheng L, Laheru DA, Jaffee EM, Le DT. A phase 2, multicenter study of FOLFIRINOX followed by ipilimumab in combination with allogeneic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer. Journal of Clinical Oncology. 32: TPS4160-TPS4160. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps4160 |
0.839 |
|
| 2014 |
Kanarek N, Lansey D, Agbahiwe HC, Brahmer JR, Jaffee EM, Wolff AC, Stearns V, Carducci MA, Zellars RC. Why is it so difficult to enroll patients in clinical trials? Journal of Clinical Oncology. 32: 6552-6552. DOI: 10.1200/Jco.2014.32.15_Suppl.6552 |
0.31 |
|
| 2014 |
Wang-Gillam A, Picozzi V, Crocenzi T, Morse M, Zeh H, Fine R, Murphy A, Skoble J, Lemmens E, Ferber S, Rosen A, Grous J, Dubensky TW, Brockstedt D, Jaffee E, et al. A Phase IIb, randomized, multicenter study of the efficacy of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously-treated metastatic pancreatic adenocarcinoma (eclipse study) Journal For Immunotherapy of Cancer. 2: P68. DOI: 10.1186/2051-1426-2-S3-P68 |
0.45 |
|
| 2014 |
Jaffee EM. Abstract SY26-01: Vaccine induced immunity against cancer genes to prevent and treat pancreatic cancer Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Sy26-01 |
0.551 |
|
| 2013 |
Salman B, Zhou D, Jaffee EM, Edil BH, Zheng L. Vaccine therapy for pancreatic cancer. Oncoimmunology. 2: e26662. PMID 24498551 DOI: 10.4161/Onci.26662 |
0.517 |
|
| 2013 |
Keenan BP, Jaffee EM, Armstrong TD. Tumor immunology: multidisciplinary science driving basic and clinical advances. Cancer Immunology Research. 1: 16-23. PMID 24409447 DOI: 10.1158/2326-6066.Cir-13-0011 |
0.532 |
|
| 2013 |
Gamrekelashvili J, Kapanadze T, Han M, Wissing J, Ma C, Jaensch L, Manns MP, Armstrong T, Jaffee E, White AO, Citrin DE, Korangy F, Greten TF. Peptidases released by necrotic cells control CD8+ T cell cross-priming. The Journal of Clinical Investigation. 123: 4755-68. PMID 24216478 DOI: 10.1172/Jci65698 |
0.49 |
|
| 2013 |
Le DT, Jaffee EM. Harnessing immune responses in the tumor microenvironment: all signals needed. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6061-3. PMID 24097857 DOI: 10.1158/1078-0432.Ccr-13-2424 |
0.473 |
|
| 2013 |
Schueneman AJ, Sugar EA, Uram J, Bigelow E, Herman JM, Edil BH, Jaffee EM, Zheng L, Laheru DA. Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine. Annals of Surgical Oncology. 20: S725-30. PMID 24046118 DOI: 10.1245/S10434-013-3262-5 |
0.794 |
|
| 2013 |
Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA, Donehower RC, Jaffee EM, Laheru DA. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 382-9. PMID 23924790 DOI: 10.1097/Cji.0B013E31829Fb7A2 |
0.803 |
|
| 2013 |
Le DT, Jaffee EM. Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 766-72. PMID 23847215 DOI: 10.6004/Jnccn.2013.0099 |
0.493 |
|
| 2013 |
Keenan B, Jaffee EM. Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance. Annals of the New York Academy of Sciences. 1284: 12-6. PMID 23651188 DOI: 10.1111/Nyas.12076 |
0.53 |
|
| 2013 |
Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 144: 1230-40. PMID 23622132 DOI: 10.1053/J.Gastro.2012.12.042 |
0.442 |
|
| 2013 |
Laheru D, Biedrzycki B, Jaffee EM. Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Methods in Molecular Biology (Clifton, N.J.). 980: 175-203. PMID 23359154 DOI: 10.1007/978-1-62703-287-2_9 |
0.567 |
|
| 2013 |
Kamiyama H, Rauenzahn S, Shim JS, Karikari CA, Feldmann G, Hua L, Kamiyama M, Schuler FW, Lin MT, Beaty RM, Karanam B, Liang H, Mullendore ME, Mo G, Hidalgo M, ... Jaffee E, et al. Personalized chemotherapy profiling using cancer cell lines from selectable mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1139-46. PMID 23340293 DOI: 10.1158/1078-0432.Ccr-12-2127 |
0.388 |
|
| 2013 |
Bigelow E, Bever KM, Xu H, Yager A, Wu A, Taube J, Chen L, Jaffee EM, Anders RA, Zheng L. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. Journal of Visualized Experiments : Jove. PMID 23328703 DOI: 10.3791/4059 |
0.384 |
|
| 2013 |
McAllister F, Bailey JM, Alsina J, Nirschl C, Roeser J, Blake D, Lankapali R, Sears C, Jaffee EM, Kolls J, Drake CG, Pardoll DM, Leach SD. TH17 cells and early pancreatic tumorigenesis. Journal of Clinical Oncology. 31: 144-144. DOI: 10.1200/Jco.2013.31.4_Suppl.144 |
0.399 |
|
| 2013 |
Le DT, Wang-Gillam A, Picozzi VJ, Greten TF, Crocenzi TS, Springett GM, Morse M, Zeh H, Cohen DJ, Fine RL, Onners B, Uram JN, Murphy A, Skoble J, Lemmens E, ... ... Jaffee EM, et al. Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 31: 4040-4040. DOI: 10.1200/Jco.2013.31.15_Suppl.4040 |
0.766 |
|
| 2013 |
Lutz E, Kinkead H, Yager A, Armstrong T, Lauer P, Brockstedt D, Dubensky T, Jaffee E. Development of mutome-specific personalized vaccines for pancreatic cancer Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P224 |
0.548 |
|
| 2013 |
Brockstedt DG, Le DT, Hassan R, Murphy A, Grous J, Dubensky TW, Jaffee EM. Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P203 |
0.524 |
|
| 2013 |
Leong M, Kanne D, Glickman L, Lemmens E, Lauer P, Metchette K, Burdette D, Diner E, Fu J, Soares K, Brockstedt D, Portnoy D, Vance R, Kim Y, Jaffee E, et al. Modified STING-activating cyclic dinucleotide derivatives significantly enhance the anti-tumor activity of therapeutic vaccines Journal For Immunotherapy of Cancer. 1: O20. DOI: 10.1186/2051-1426-1-S1-O20 |
0.485 |
|
| 2013 |
Jaffee E. Abstract CN01-02: Tipping the balance from a procarcinogenic to an anticancer response to prevent pancreatic cancer Cancer Prevention Research. 6. DOI: 10.1158/1940-6215.Prev-13-Cn01-02 |
0.532 |
|
| 2013 |
Soares KC, Olino K, Edil B, Zhou D, Wamwea A, Leubner A, Schulick R, Pardoll D, Jaffee E, Zheng L. Abstract PR9: Granulocyte macrophage colony stimulating factor (GM-CSF) pancreas tumor vaccine in combination with blockade of PD-1 in a preclinical model of pancreatic cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-Pr9 |
0.486 |
|
| 2013 |
Keenan B, Saenger Y, Kafrouni M, Leubner A, Lauer P, Maitra A, Gunderson A, Coussens L, Armstrong T, Jaffee E. Abstract 489: Prevention of pancreatic intra-epithelial neoplasm progression by a Listeria monocytogenes vaccine targeting mutated Kras, an early genetic event in pancreatic tumor development. Cancer Research. 73: 489-489. DOI: 10.1158/1538-7445.Tumimm2012-Pr6 |
0.586 |
|
| 2013 |
Jaffee E. Abstract IA10: Tipping the balance from a procarcinogenic to anticancer response in pancreatic cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-Ia10 |
0.545 |
|
| 2013 |
Kouo TS, Huang L, Armstrong T, Jaffee EM. Abstract B59: Regulation of tumor-specific CD8 T cells via interactions between galectin-3 and surface glycoproteins. Cancer Research. 73: 1263-1263. DOI: 10.1158/1538-7445.Tumimm2012-B59 |
0.53 |
|
| 2013 |
Black CM, Armstrong TD, Jaffee EM. Abstract B54: Low avidity tumor-specific CD8+ T cells are regulated by increased expression of proapoptotic proteins in tolerant mice. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B54 |
0.845 |
|
| 2013 |
Jhaveri DT, Kim M, Huang L, Sharma R, Anders RA, Pandey A, Jaffee EM. Abstract B52: A novel quantitative proteomics approach to identify proteins that elicit antibody responses in vaccinated pancreatic cancer patients. Cancer Research. 73: 2485-2485. DOI: 10.1158/1538-7445.Tumimm2012-B52 |
0.483 |
|
| 2013 |
Ng J, Uram J, Onners B, Biedrzycki B, Sugar E, Solt S, Armstrong T, Le D, Zheng L, Schroeder J, Jaffee E, Laheru D. Abstract B27: IgE-independent hypersensitvity reactions are associated with prolonged survival in advanced pancreatic cancer patients receiving a GM-CSF cell-based vaccine plus cyclophosphamide (Cy) and cetuximab. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B27 |
0.803 |
|
| 2013 |
Wang Q, Li S, Wang H, Xiao Y, Sahin O, Brady SW, Li P, Jaffee EM, Hortobagyi GN, Yu D. Abstract LB-215: Concomitant targeting of tumor cells and induction of T cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-215 |
0.535 |
|
| 2013 |
Black CM, Jaffee EM, Armstrong TD. Abstract 455: Pro-apoptotic proteins affect survival of tumor-specific low avidity CD8 + T cells in tolerant mice. Cancer Research. 73: 455-455. DOI: 10.1158/1538-7445.Am2013-455 |
0.842 |
|
| 2013 |
Foley K, Zhou D, Xiao Q, Rucki A, Mo G, Huang L, Maitra A, Jaffee E, Zheng L. Abstract 3935: AnnexinA2 regulates invasion and metastasis of pancreatic ductal adenocarcinoma through Semaphorin3d. Cancer Research. 73: 3935-3935. DOI: 10.1158/1538-7445.Am2013-3935 |
0.738 |
|
| 2013 |
McAllister F, Bailey JM, Alsina J, Nirschl C, Lankapalli R, Roeser J, Jaffee E, Sears C, Kolls JK, Drake CG, Pardoll DM, Leach SD. Abstract 2867: TH17 cells promote early pancreatic tumorigenesis. Cancer Research. 73: 2867-2867. DOI: 10.1158/1538-7445.Am2013-2867 |
0.402 |
|
| 2013 |
Mauro LA, Herman JM, Jaffee EM, Laheru DA. Carcinoma of the Pancreas Abeloff's Clinical Oncology: Fifth Edition. 1397-1415.e7. DOI: 10.1016/B978-1-4557-2865-7.00081-3 |
0.322 |
|
| 2012 |
Le DT, Lutz E, Huang L, Onners B, Uram J, Solt S, Sugar E, Zheng L, Jaffee EM, Laheru D. Phase Ib study of ipilimumab alone or in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene (vaccine) in pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 211. PMID 27983204 DOI: 10.1200/Jco.2012.30.4_Suppl.211 |
0.791 |
|
| 2012 |
Rudra S, Narang AK, Pawlik TM, Wang H, Jaffee EM, Zheng L, Le DT, Cosgrove D, Hruban RH, Fishman EK, Tuli R, Laheru DA, Wolfgang CL, Diaz LA, Herman JM. Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation. Practical Radiation Oncology. 2: 77-85. PMID 23585823 DOI: 10.1016/J.Prro.2011.06.009 |
0.314 |
|
| 2012 |
Soares KC, Zheng L, Edil B, Jaffee EM. Vaccines for pancreatic cancer. Cancer Journal (Sudbury, Mass.). 18: 642-52. PMID 23187853 DOI: 10.1097/Ppo.0B013E3182756903 |
0.473 |
|
| 2012 |
Weiss VL, Lee TH, Jaffee EM, Armstrong TD. Targeting the right regulatory T-cell population for tumor immunotherapy. Oncoimmunology. 1: 1191-1193. PMID 23170276 DOI: 10.4161/Onci.20664 |
0.76 |
|
| 2012 |
Kim MS, Kuppireddy SV, Sakamuri S, Singal M, Getnet D, Harsha HC, Goel R, Balakrishnan L, Jacob HK, Kashyap MK, Tankala SG, Maitra A, Iacobuzio-Donahue CA, Jaffee E, Goggins MG, et al. Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). Journal of Proteome Research. 11: 5556-63. PMID 22985314 DOI: 10.1021/Pr300483R |
0.406 |
|
| 2012 |
Wang Q, Li SH, Wang H, Xiao Y, Sahin O, Brady SW, Li P, Ge H, Jaffee EM, Muller WJ, Hortobagyi GN, Yu D. Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer. Cancer Research. 72: 4417-28. PMID 22773664 DOI: 10.1158/0008-5472.Can-12-1339-T |
0.529 |
|
| 2012 |
Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Research. 72: 3439-44. PMID 22761338 DOI: 10.1158/0008-5472.Can-11-3912 |
0.515 |
|
| 2012 |
Zheng L, Jaffee EM. Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy. Oncoimmunology. 1: 112-114. PMID 22720228 DOI: 10.4161/Onci.1.1.18017 |
0.452 |
|
| 2012 |
Keenan BP, Jaffee EM. Whole cell vaccines--past progress and future strategies. Seminars in Oncology. 39: 276-86. PMID 22595050 DOI: 10.1053/J.Seminoncol.2012.02.007 |
0.534 |
|
| 2012 |
Tuli R, Surmak A, Reyes J, Hacker-Prietz A, Armour M, Leubner A, Blackford A, Tryggestad E, Jaffee EM, Wong J, Deweese TL, Herman JM. Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenografts. Translational Oncology. 5: 77-84. PMID 22496923 DOI: 10.1593/Tlo.11316 |
0.402 |
|
| 2012 |
Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nature Reviews. Cancer. 12: 307-13. PMID 22378190 DOI: 10.1038/Nrc3246 |
0.38 |
|
| 2012 |
Weiss VL, Lee TH, Song H, Kouo TS, Black CM, Sgouros G, Jaffee EM, Armstrong TD. Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells. Plos One. 7: e31962. PMID 22359647 DOI: 10.1371/Journal.Pone.0031962 |
0.85 |
|
| 2012 |
Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, ... ... Jaffee EM, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 858-68. PMID 22147941 DOI: 10.1158/1078-0432.Ccr-11-2121 |
0.527 |
|
| 2012 |
Schueneman A, Sugar E, Uram J, Bigelow E, Herman JM, Edil BH, Jaffee EM, Zheng L, Laheru D. Association of low total lymphocyte count with overall and disease-free survival in patients with resected pancreatic adenocarcinoma receiving the GM-CSF secreting pancreatic tumor vaccine in combination with adjuvant chemoradiation. Journal of Clinical Oncology. 30: e14585-e14585. DOI: 10.1200/Jco.2012.30.15_Suppl.E14585 |
0.796 |
|
| 2012 |
McAllister F, Bailey JM, Roeser J, Blake DT, Wick EC, Sears CL, Jaffee EM, Kolls JK, Drake CG, Pardoll DM, Leach SD. Abstract 2968: TH17 cells in early pancreatic tumorigenesis Cancer Research. 72: 2968-2968. DOI: 10.1158/1538-7445.Am2012-2968 |
0.415 |
|
| 2011 |
Emens LA, Gupta R, Petrik S, Laiko M, Leatherman JM, Levi J, Asquith JM, Daphtary MM, Garrett-Mayer E, Kobrin BJ, Davidson NE, Dauses T, Atay-Rosenthal S, Ye X, Wolff AC, ... ... Jaffee EM, et al. A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2535. PMID 28022330 DOI: 10.1200/Jco.2011.29.15_Suppl.2535 |
0.537 |
|
| 2011 |
Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, ... ... Jaffee EM, et al. Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. 9: 214. PMID 22168571 DOI: 10.1186/1479-5876-9-214 |
0.377 |
|
| 2011 |
Mathews LA, Cabarcas SM, Hurt EM, Zhang X, Jaffee EM, Farrar WL. Increased expression of DNA repair genes in invasive human pancreatic cancer cells. Pancreas. 40: 730-9. PMID 21633318 DOI: 10.1097/Mpa.0B013E31821Ae25B |
0.401 |
|
| 2011 |
Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K, Edil BH, Mizuma M, Sharma R, Le DT, Anders RA, Illei PB, Van Eyk JE, Maitra A, Laheru D, ... Jaffee EM, et al. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. Plos One. 6: e19390. PMID 21572519 DOI: 10.1371/Journal.Pone.0019390 |
0.726 |
|
| 2011 |
Balwit JM, Kalinski P, Sondak VK, Coulie PG, Jaffee EM, Gajewski TF, Marincola FM. Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. Journal of Translational Medicine. 9: 60. PMID 21569425 DOI: 10.1186/1479-5876-9-60 |
0.47 |
|
| 2011 |
Uram JN, Black CM, Flynn E, Huang L, Armstrong TD, Jaffee EM. Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. Journal of Immunology (Baltimore, Md. : 1950). 186: 3847-57. PMID 21346233 DOI: 10.4049/Jimmunol.1000361 |
0.837 |
|
| 2011 |
Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, ... ... Jaffee E, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Annals of Surgery. 253: 328-35. PMID 21217520 DOI: 10.1097/Sla.0B013E3181Fd271C |
0.467 |
|
| 2011 |
Le DT, Ladle BH, Lee T, Weiss V, Yao X, Leubner A, Armstrong TD, Jaffee EM. CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. International Journal of Cancer. 129: 636-47. PMID 20857491 DOI: 10.1002/Ijc.25693 |
0.84 |
|
| 2011 |
Tuli R, Surmak A, Blackford A, Leubner A, Jaffee EM, DeWeese TL, Herman JM. Effect of inhibition of poly-(ADP ribose) polymerase on gemcitabine and radiation-induced cytotoxicity of pancreatic cancer cells. Journal of Clinical Oncology. 29: 203-203. DOI: 10.1200/Jco.2011.29.4_Suppl.203 |
0.384 |
|
| 2010 |
Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4390-9. PMID 20697078 DOI: 10.1200/Jco.2009.27.6360 |
0.408 |
|
| 2010 |
Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer Journal (Sudbury, Mass.). 16: 304-10. PMID 20693840 DOI: 10.1097/Ppo.0B013E3181Eb33D7 |
0.532 |
|
| 2010 |
Pfannenstiel LW, Lam SS, Emens LA, Jaffee EM, Armstrong TD. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cellular Immunology. 263: 79-87. PMID 20346445 DOI: 10.1016/J.Cellimm.2010.03.001 |
0.828 |
|
| 2010 |
Weiss VL, Lee TH, Armstrong TD, Jaffee EM. Abstract 1923: Regulatory T-cell subsets suppress high avidity CD8 T-cell activation and trafficking Cancer Research. 70: 1923-1923. DOI: 10.1158/1538-7445.Am10-1923 |
0.792 |
|
| 2010 |
Tuli R, Surmak A, Blackford A, Reyes J, Leubner A, Zhang Y, Zhou H, Jaffee E, DeWeese T, Herman J. Poly (ADP Ribose) Polymerase Inhibition with ABT-888 Alone and in Combination with Gemcitabine Enhances Radiosensitization of Pancreatic Cancer Cells International Journal of Radiation Oncology*Biology*Physics. 78: S653-S654. DOI: 10.1016/J.Ijrobp.2010.07.1521 |
0.398 |
|
| 2009 |
Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, ... ... Jaffee EM, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5911-8. PMID 19805669 DOI: 10.1200/Jco.2009.23.3494 |
0.473 |
|
| 2009 |
Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Eshleman JR, Goggins M, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Cameron JL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4674-9. PMID 19584151 DOI: 10.1158/1078-0432.Ccr-09-0227 |
0.346 |
|
| 2009 |
Kitamura N, Murata S, Ueki T, Mekata E, Reilly RT, Jaffee EM, Tani T. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity. International Journal of Cancer. Journal International Du Cancer. 125: 630-8. PMID 19455675 DOI: 10.1002/Ijc.24435 |
0.468 |
|
| 2009 |
Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JCH, Palmisano E, Brune K, Jaffee EM, Iacobuzio-Donahue CA, Maitra A, Parmigiani G, Kern SE, Velculescu VE, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene Science. 324: 217. PMID 19264984 DOI: 10.1126/Science.1171202 |
0.321 |
|
| 2009 |
Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet (London, England). 373: 673-83. PMID 19231634 DOI: 10.1016/S0140-6736(09)60404-9 |
0.493 |
|
| 2009 |
Jaffee EM. 177 Recruitment of high avidity antigen-specific T cells in pancreatic cancer patients Jaids Journal of Acquired Immune Deficiency Syndromes. 51: 1. DOI: 10.1097/01.qai.0000351236.58733.11 |
0.38 |
|
| 2008 |
Laheru DA, Cohen SJ, Phillips M, Armstrong DK, Brahmer J, Jaffee EM, Weil S, Pastan I, Hassan R. A phase I study of MORab-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3578. PMID 27949713 DOI: 10.1200/Jco.2008.26.15_Suppl.3578 |
0.463 |
|
| 2008 |
Leao IC, Ganesan P, Armstrong TD, Jaffee EM. Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clinical and Translational Science. 1: 228-39. PMID 20357913 DOI: 10.1111/j.1752-8062.2008.00070.x |
0.497 |
|
| 2008 |
Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, ... ... Jaffee EM, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, N.Y.). 321: 1801-6. PMID 18772397 DOI: 10.1126/Science.1164368 |
0.375 |
|
| 2008 |
Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, Campbell KA, Wolfgang CL, Asrari F, Donehower R, Hidalgo M, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3503-10. PMID 18640931 DOI: 10.1200/Jco.2007.15.8469 |
0.303 |
|
| 2008 |
Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S, Sgouros G, Emens LA, Reilly RT, Jaffee EM. Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. The Journal of Clinical Investigation. 118: 1700-11. PMID 18398507 DOI: 10.1172/Jci34333 |
0.785 |
|
| 2008 |
Miyashita T, Shah FA, Marti GP, Armstrong TD, Wang J, Bonde P, Gibson MK, Yoshimura K, Montgomery EA, Duncan M, Jaffee EM, Harmon JW. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting. Digestive Diseases and Sciences. 53: 2858-67. PMID 18343998 DOI: 10.1007/S10620-008-0232-Z |
0.452 |
|
| 2008 |
Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 1455-63. PMID 18316569 DOI: 10.1158/1078-0432.Ccr-07-0371 |
0.449 |
|
| 2008 |
Miyashita T, Shah FA, Marti G, Wang J, Armstrong T, Bonde P, Gibson MK, Yoshimura K, Montgomery EA, Duncan MD, Jaffee EM, Harmon JW. Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 12: 2-7; discussion 7-9. PMID 17957441 DOI: 10.1007/S11605-007-0337-2 |
0.428 |
|
| 2008 |
Emens LA, Asquith JM, Leatherman JM, Daphtary MM, Petrik S, Fetting JH, Disis ML, Piantadosi S, Davidson NE, Jaffee EM. Increasing doses of cyclophosphamide suppress antigen-specific T helper-dependent immunity induced by a GM-CSF-secreting breast tumor vaccine Journal of Clinical Oncology. 26: 3009-3009. DOI: 10.1200/Jco.2008.26.15_Suppl.3009 |
0.468 |
|
| 2008 |
Kafrouni M, Armstrong T, Jaffee EM. 318 Early Vaccination Targeting Mutated KRAS As An Antigen Expressed By Panins Delays Progression to Pancreatic Tumors in a Mouse Model Gastroenterology. 134: A-46. DOI: 10.1016/S0016-5085(08)60221-8 |
0.455 |
|
| 2007 |
Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immunity. 7: 20. PMID 18088084 |
0.394 |
|
| 2007 |
Couch ME, Ferris RL, Brennan JA, Koch WM, Jaffee EM, Leibowitz MS, Nepom GT, Erlich HA, Sidransky D. Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7199-206. PMID 18056201 DOI: 10.1158/1078-0432.Ccr-07-0682 |
0.326 |
|
| 2007 |
Moran TP, Burgents JE, Long B, Ferrer I, Jaffee EM, Tisch RM, Johnston RE, Serody JS. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine. 25: 6604-12. PMID 17675184 DOI: 10.1016/J.Vaccine.2007.06.058 |
0.541 |
|
| 2007 |
Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, Hicklin DJ, Jaffee EM, Emens LA. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 3951-9. PMID 17606729 DOI: 10.1158/1078-0432.Ccr-07-0374 |
0.391 |
|
| 2007 |
Prendergast GC, Jaffee EM. Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Research. 67: 3500-4. PMID 17413003 DOI: 10.1158/0008-5472.Can-06-4626 |
0.508 |
|
| 2007 |
Bonde P, Sui G, Dhara S, Wang J, Broor A, Kim IF, Wiley JE, Marti G, Duncan M, Jaffee E, Montgomery E, Maitra A, Harmon JW. Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model. The Journal of Thoracic and Cardiovascular Surgery. 133: 763-9. PMID 17320581 DOI: 10.1016/J.Jtcvs.2006.07.044 |
0.406 |
|
| 2007 |
Lin KY, Lu D, Hung CF, Peng S, Huang L, Jie C, Murillo F, Rowley J, Tsai YC, He L, Kim DJ, Jaffee E, Pardoll D, Wu TC. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Research. 67: 1832-41. PMID 17308126 DOI: 10.1158/0008-5472.Can-06-3014 |
0.516 |
|
| 2007 |
Laheru D, Yeo C, Biedrzycki B, Solt S, Lutz E, Onners B, Tartakovsky I, Herman J, Hruban R, Piantadosi S, Jaffee E. A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas Journal of Clinical Oncology. 25: 3010-3010. DOI: 10.1200/Jco.2007.25.18_Suppl.3010 |
0.492 |
|
| 2006 |
Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Advances in Immunology. 90: 51-81. PMID 16730261 DOI: 10.1016/S0065-2776(06)90002-9 |
0.419 |
|
| 2006 |
Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar S. Ductal access for prevention and therapy of mammary tumors Cancer Research. 66: 638-645. PMID 16423990 DOI: 10.1158/0008-5472.Can-05-4329 |
0.372 |
|
| 2006 |
Murata S, Ladle BH, Kim PS, Lutz ER, Wolpoe ME, Ivie SE, Smith HM, Armstrong TD, Emens LA, Jaffee EM, Reilly RT. OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen. Journal of Immunology (Baltimore, Md. : 1950). 176: 974-83. PMID 16393983 DOI: 10.4049/Jimmunol.176.2.974 |
0.823 |
|
| 2005 |
Laheru DA, Pardoll DM, Jaffee EM. Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. Molecular Cancer Therapeutics. 4: 1645-52. PMID 16275985 DOI: 10.1158/1535-7163.Mct-05-0151 |
0.498 |
|
| 2005 |
Emens LA, Reilly RT, Jaffee EM. Cancer vaccines in combination with multimodality therapy. Cancer Treatment and Research. 123: 227-45. PMID 16211873 DOI: 10.1007/0-387-27545-2_10 |
0.499 |
|
| 2005 |
Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Research. 65: 8059-64. PMID 16166275 DOI: 10.1158/0008-5472.Can-05-1797 |
0.535 |
|
| 2005 |
Singh R, Dominiecki ME, Jaffee EM, Paterson Y. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. Journal of Immunology (Baltimore, Md. : 1950). 175: 3663-73. PMID 16148111 DOI: 10.4049/Jimmunol.175.6.3663 |
0.488 |
|
| 2005 |
Gandini S, Lowenfels AB, Jaffee EM, Armstrong TD, Maisonneuve P. Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 14: 1908-16. PMID 16103436 DOI: 10.1158/1055-9965.Epi-05-0119 |
0.324 |
|
| 2005 |
Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. Nature Reviews. Cancer. 5: 459-67. PMID 15905855 DOI: 10.1038/Nrc1630 |
0.407 |
|
| 2005 |
Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. The Journal of Experimental Medicine. 201: 1591-602. PMID 15883172 DOI: 10.1084/Jem.20042167 |
0.823 |
|
| 2005 |
Emens LA, Reilly RT, Jaffee EM. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocrine-Related Cancer. 12: 1-17. PMID 15788636 DOI: 10.1677/Erc.1.00671 |
0.451 |
|
| 2005 |
Zhou X, Jun DY, Thomas AM, Huang X, Huang LQ, Mautner J, Mo W, Robbins PF, Pardoll DM, Jaffee EM. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Research. 65: 1079-88. PMID 15705910 |
0.464 |
|
| 2005 |
Mautner J, Jaffee EM, Pardoll DM. Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens. International Journal of Cancer. 115: 752-9. PMID 15704175 DOI: 10.1002/Ijc.20927 |
0.525 |
|
| 2005 |
Laheru D, Biedrzycki B, Thomas AM, Jaffee EM. Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Methods in Molecular Medicine. 103: 299-327. PMID 15542914 DOI: 10.1385/1-59259-780-7:299 |
0.567 |
|
| 2005 |
Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene. 24: 39-46. PMID 15489885 DOI: 10.1038/Sj.Onc.1208174 |
0.348 |
|
| 2005 |
Jun DY, Jaffee EM, Kim YH. Application of Apoptogenic Pretreatment to Enhance Anti-tumor Immunity of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)-secreting CT26 Tumor Cells Immune Network. 5: 110. DOI: 10.4110/In.2005.5.2.110 |
0.467 |
|
| 2005 |
Jaffee E. Recruitment of High Avidity Antigen Specific T Cells With T Regulatory Cell Modulation Journal of Immunotherapy. 28: 649. DOI: 10.1097/01.Cji.0000191068.19254.43 |
0.42 |
|
| 2005 |
Brockstedt DG, Hampl J, Bahjat K, Lutz E, Leong M, Liu W, Pardoll D, Giedlin M, Jaffee E, Dubensky T. Characterization of Mesothelin-Specific T Cell Responses in Healthy Individuals Journal of Immunotherapy. 28: 631. DOI: 10.1097/01.Cji.0000191007.62728.66 |
0.385 |
|
| 2005 |
Davis-Sproul J, Harris M, Davidson N, Kobrin B, Jaffee E, Emens L. Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility Cytotherapy. 7: 46-56. DOI: 10.1016/S1465-3249(05)70788-X |
0.452 |
|
| 2004 |
Emens LA, Reilly RT, Jaffee EM. Augmenting the potency of breast cancer vaccines: combined modality immunotherapy. Breast Disease. 20: 13-24. PMID 15687703 DOI: 10.3233/Bd-2004-20103 |
0.49 |
|
| 2004 |
Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. The Journal of Experimental Medicine. 200: 297-306. PMID 15289501 DOI: 10.1084/Jem.20031435 |
0.562 |
|
| 2004 |
Sui G, Bonde P, Dhara S, Marti G, Freguson M, Wang J, Jaffee E, Duncan M, Montgomery E, Maitra A, Harmon J. Inhibition of the EGFR and hedgehog signaling pathways demonstrate potent growth inhibition in an animal model of esophageal carcinogenesis Journal of Surgical Research. 121: 278-279. DOI: 10.1016/J.Jss.2004.07.040 |
0.37 |
|
| 2003 |
Emens LA, Jaffee EM. Toward a breast cancer vaccine: work in progress. Oncology (Williston Park, N.Y.). 17: 1200-11; discussion . PMID 14569849 |
0.335 |
|
| 2003 |
Emens LA, Jaffee EM. Cancer vaccines: an old idea comes of age. Cancer Biology & Therapy. 2: S161-8. PMID 14508095 DOI: 10.4161/Cbt.217 |
0.483 |
|
| 2003 |
Wolpoe ME, Lutz ER, Ercolini AM, Murata S, Ivie SE, Garrett ES, Emens LA, Jaffee EM, Reilly RT. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 171: 2161-9. PMID 12902523 DOI: 10.4049/Jimmunol.171.4.2161 |
0.573 |
|
| 2003 |
Couch M, Saunders JK, O'Malley BW, Pardoll D, Jaffee E. Spatial distribution of tumor vaccine improves efficacy. The Laryngoscope. 113: 1401-5. PMID 12897566 DOI: 10.1097/00005537-200308000-00026 |
0.447 |
|
| 2003 |
Zhou X, Cui Y, Huang X, Yu Z, Thomas AM, Ye Z, Pardoll DM, Jaffee EM, Cheng L. Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Human Gene Therapy. 14: 1089-105. PMID 12885348 DOI: 10.1089/104303403322124800 |
0.451 |
|
| 2003 |
Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT, Jaffee EM. Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 170: 4273-80. PMID 12682262 DOI: 10.4049/Jimmunol.170.8.4273 |
0.488 |
|
| 2003 |
Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. The American Journal of Pathology. 162: 1151-62. PMID 12651607 DOI: 10.1016/S0002-9440(10)63911-9 |
0.38 |
|
| 2003 |
Couch M, Saunders JK, O'Malley BW, Pardoll D, Jaffee E. Genetically engineered tumor cell vaccine in a head and neck cancer model. The Laryngoscope. 113: 552-6. PMID 12616213 DOI: 10.1097/00005537-200303000-00029 |
0.49 |
|
| 2003 |
Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, Manns MP, Greten TF. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. International Journal of Cancer. 103: 205-11. PMID 12455034 DOI: 10.1002/Ijc.10777 |
0.551 |
|
| 2003 |
Jun DY, Moutner J, Jaffee E. Generation of Renal Cell Carcinoma-specific CD4+/CD8+T Cells Restricted by an HLA-39 from a RCC Patient Vaccinated with GM-CSF Gene-Transduced Tumor Cells Immune Network. 3: 96. DOI: 10.4110/In.2003.3.2.96 |
0.564 |
|
| 2002 |
Armstrong TD, Jaffee EM. Cytokine modified tumor vaccines. Surgical Oncology Clinics of North America. 11: 681-96. PMID 12487062 DOI: 10.1016/S1055-3207(02)00020-0 |
0.489 |
|
| 2002 |
Warren EH, Tykodi SS, Murata M, Sandmaier BM, Storb R, Jaffee E, Childs R, Thompson JA, Greenberg PD, Riddell SR. T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma. Cytotherapy. 4: 441. PMID 12473218 DOI: 10.1080/146532402320776116 |
0.436 |
|
| 2002 |
Emens LA, Jaffee EM. To live or not to live: that depends on GAGE? Cancer Biology & Therapy. 1: 388-90. PMID 12432252 DOI: 10.4161/Cbt.1.4.12 |
0.326 |
|
| 2002 |
Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer Cell. 2: 25-8. PMID 12150822 DOI: 10.1016/S1535-6108(02)00093-4 |
0.334 |
|
| 2002 |
Reilly RT, Machiels JP, Emens LA, Jaffee EM. Cytokine gene-modified cell-based cancer vaccines. Methods in Molecular Medicine. 69: 233-57. PMID 11987781 DOI: 10.1385/1-59259-141-8:233 |
0.554 |
|
| 2002 |
Ueki T, Walter KM, Skinner H, Jaffee E, Hruban RH, Goggins M. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene. 21: 2114-7. PMID 11960385 DOI: 10.1038/Sj.Onc.1205275 |
0.365 |
|
| 2001 |
Greten TF, Jaffee EM. Cancer vaccines. Current Protocols in Human Genetics / Editorial Board, Jonathan L. Haines ... [Et Al.]. Unit 13.8. PMID 18428256 DOI: 10.1002/0471142905.Hg1308S14 |
0.436 |
|
| 2001 |
Wesseling JG, Bosma PJ, Krasnykh V, Kashentseva EA, Blackwell JL, Reynolds PN, Li H, Parameshwar M, Vickers SM, Jaffee EM, Huibregtse K, Curiel DT, Dmitriev I. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Therapy. 8: 969-76. PMID 11438831 DOI: 10.1038/Sj.Gt.3301473 |
0.313 |
|
| 2001 |
Golgher D, Korangy F, Gao B, Gorski K, Jaffee E, Edidin M, Pardoll DM, Elliott T. An immunodominant MHC class II-restricted tumor antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin Journal of Immunology. 167: 147-155. PMID 11418643 DOI: 10.4049/Jimmunol.167.1.147 |
0.416 |
|
| 2001 |
Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD, O'Reilly S, Abrams RA, Pardoll DM, Cameron JL, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 145-56. PMID 11134207 DOI: 10.1200/Jco.2001.19.1.145 |
0.51 |
|
| 2000 |
Chakravarthy A, Abrams RA, Yeo CJ, Korman LT, Donehower RC, Hruban RH, Zahurek ML, Grochow LB, O'Reilly S, Hurwitz H, Jaffee EM, Lillemoe KD, Cameron JL. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. International Journal of Radiation Oncology, Biology, Physics. 48: 1089-96. PMID 11072167 DOI: 10.1016/S0360-3016(00)00755-0 |
0.329 |
|
| 2000 |
Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex Immunity. 13: 529-538. PMID 11070171 DOI: 10.1016/S1074-7613(00)00052-2 |
0.45 |
|
| 2000 |
Ewend MG, Thompson RC, Anderson R, Sills AK, Staveley-O'Carroll K, Tyler BM, Hanes J, Brat D, Thomas M, Jaffee EM, Pardoll DM, Brem H. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 438-48. PMID 10916753 DOI: 10.1097/00002371-200007000-00007 |
0.465 |
|
| 2000 |
Ferrone S, Finerty JF, Jaffee EM, Nabel GJ. How much longer will tumour cells fool the immune system? Immunology Today. 21: 70-2. PMID 10712001 DOI: 10.1016/S0167-5699(99)01569-8 |
0.393 |
|
| 2000 |
Jaffee EM. Immunotherapy of cancer. Annals of the New York Academy of Sciences. 886: 67-72. PMID 10667204 DOI: 10.1111/J.1749-6632.1999.Tb09401.X |
0.573 |
|
| 2000 |
Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Advances in Immunology. 74: 181-273. PMID 10605607 DOI: 10.1016/S0065-2776(08)60911-6 |
0.539 |
|
| 2000 |
Jaffee EM. Progress Toward Cancer Vaccines Hospital Practice. 35: 49-65. DOI: 10.3810/Hp.2000.12.220 |
0.411 |
|
| 2000 |
Ueki T, Toyota M, Walter KM, Jaffee E, Yeo CJ, Hruban RH, Goggins M. High concordance between DNA methylation of tumor suppressor loci in pancreatic cancer cell lines and their corresponding primary carcinoma Gastroenterology. 118: A46. DOI: 10.1016/S0016-5085(00)82253-2 |
0.404 |
|
| 1999 |
Greten TF, Jaffee EM. Cancer vaccines. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 17: 1047-60. PMID 10071300 DOI: 10.1200/jco.1999.17.3.1047 |
0.483 |
|
| 1998 |
Goggins M, Lietman A, Miller RE, Yeo CJ, Jaffee E, Coleman J, O'Reilly S, Cullen B, Cameron JL, Kern SE, Hruban RH. Use and benefits of a Web site for pancreatic cancer. Jama. 280: 1309-1310. PMID 9794306 DOI: 10.1001/Jama.280.15.1309-A |
0.309 |
|
| 1998 |
Jaffee EM, Abrams R, Cameron J, Donehower R, Duerr M, Gossett J, Greten TF, Grochow L, Hruban R, Kern S, Lillemoe KD, O'Reilly S, Pardoll D, Pitt HA, Sauter P, et al. A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland Human Gene Therapy. 9: 1951-1971. PMID 9741433 DOI: 10.1089/Hum.1998.9.13-1951 |
0.407 |
|
| 1998 |
Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, Pardoll DM, Jacobson S, Schneck JP. Direct visualization of antigen-specific T cells: HTLV-1 TAX11-19- specific CD8+ T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients Proceedings of the National Academy of Sciences of the United States of America. 95: 7568-7573. PMID 9636190 DOI: 10.1073/Pnas.95.13.7568 |
0.409 |
|
| 1998 |
Thomas MC, Greten TF, Pardoll DM, Jaffee EM. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Human Gene Therapy. 9: 835-43. PMID 9581906 DOI: 10.1089/Hum.1998.9.6-835 |
0.542 |
|
| 1998 |
Simons J, Jaffee E, Weber C, Levitsky H, Nelson W, Carducci M, Lazenby A, Cohen L, Finn C, Clift S, Hauda K, Beck L, Leiferman K, Owens A, Piantadosi S, et al. Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by Ex Vivo Granulocyte-Macrophage Colony-Stimulating Factor Gene Transfer Journal of Urology. 159: 617-618. DOI: 10.1016/S0022-5347(01)63906-5 |
0.347 |
|
| 1997 |
Jaffee EM, Pardoll DM. Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods (San Diego, Calif.). 12: 143-53. PMID 9184378 DOI: 10.1006/Meth.1997.0463 |
0.504 |
|
| 1997 |
Jaffee EM, Pardoll DM. Murine tumor antigens: is it worth the search? Current Opinion in Immunology. 8: 622-7. PMID 8902386 DOI: 10.1016/S0952-7915(96)80077-X |
0.486 |
|
| 1997 |
Griffin C, Morsberger L, Jaffee E, Perlman E. CGH analysis of pancreatic adenocarcinoma cell lines Cancer Genetics and Cytogenetics. 98: 159. DOI: 10.1016/S0165-4608(97)90279-X |
0.327 |
|
| 1996 |
Thompson RC, Pardoll DM, Jaffee EM, Ewend MG, Thomas MC, Tyler BM, Brem H. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 19: 405-13. PMID 9041459 DOI: 10.1097/00002371-199611000-00004 |
0.462 |
|
| 1996 |
Jaffee EM, Thomas MC, Huang AY, Hauda KM, Levitsky HI, Pardoll DM. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 19: 176-83. PMID 8811492 DOI: 10.1097/00002371-199605000-00002 |
0.459 |
|
| 1996 |
Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM, Jaffee EM. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proceedings of the National Academy of Sciences of the United States of America. 93: 9730-5. PMID 8790399 DOI: 10.1073/Pnas.93.18.9730 |
0.433 |
|
| 1995 |
Jaffee EM, Lazenby A, Meurer J, Marshall F, Hauda KM, Counts C, Hurwitz H, Simons JW, Levitsky HI, Pardoll DM. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 18: 1-9. PMID 8535565 DOI: 10.1097/00002371-199507000-00001 |
0.479 |
|
| 1995 |
Woods AS, Huang AY, Cotter RJ, Pasternack GR, Pardoll DM, Jaffee EM. Simplified high-sensitivity sequencing of a major histocompatibility complex class I-associated immunoreactive peptide using matrix-assisted laser desorption/ionization mass spectrometry. Analytical Biochemistry. 226: 15-25. PMID 7785766 DOI: 10.1006/Abio.1995.1185 |
0.372 |
|
| 1995 |
Berns AJ, Clift S, Cohen LK, Donehower RC, Dranoff G, Hauda KM, Jaffee EM, Lazenby AJ, Levitsky HI, Marshall FF. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Human Gene Therapy. 6: 347-68. PMID 7779918 DOI: 10.1089/Hum.1995.6.3-347 |
0.394 |
|
| 1995 |
Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. The Journal of Experimental Medicine. 182: 1415-21. PMID 7595212 DOI: 10.1084/Jem.182.5.1415 |
0.446 |
|
| 1995 |
Griffin C, Hruban R, Morsberger L, Ellingham T, Long P, Jaffee E, Houda K, Bohlander S, Yeo C. Consistent chromosome abnormalities in adenocarcinoma of the pancreas Cancer Genetics and Cytogenetics. 84: 136. DOI: 10.1016/0165-4608(96)85235-6 |
0.317 |
|
| 1994 |
Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW. Demonstration of a rational strategy for human prostate cancer gene therapy. The Journal of Urology. 151: 622-8. PMID 8308972 DOI: 10.1016/S0022-5347(17)35032-2 |
0.351 |
|
| 1994 |
Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (New York, N.Y.). 264: 961-5. PMID 7513904 DOI: 10.1126/Science.7513904 |
0.488 |
|
| 1993 |
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences of the United States of America. 90: 3539-43. PMID 8097319 DOI: 10.1073/Pnas.90.8.3539 |
0.543 |
|
| 1993 |
Golumbek PT, Hamzeh FM, Jaffee EM, Levitsky H, Lietman PS, Pardoll DM. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 12: 224-30. PMID 1335754 DOI: 10.1097/00002371-199211000-00002 |
0.508 |
|
| Show low-probability matches. |